Collegium Pharmaceutical (COLL) 10-Q7 May 202020 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	Apr. 30, 2020
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-37372
Entity Registrant Name	Collegium Pharmaceutical, Inc.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	03-0416362
Entity Address, Address Line One	100 Technology Center Drive
Entity Address, City or Town	Stoughton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02072
City Area Code	781
Local Phone Number	713-3699
Title of 12(b) Security	Common Stock
Trading Symbol	COLL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,336,032
Entity Central Index Key	0001267565
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONDENSED CONSOLIDATE

CONDENSED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 116,178	$ 170,019
Accounts receivable	85,427	72,953
Inventory	15,963	9,643
Prepaid expenses and other current assets	6,107	3,105
Total current assets	223,675	255,720
Property and equipment, net	13,145	11,854
Operating lease assets	8,873	9,047
Intangible asset, net	386,289	29,503
Restricted cash	2,645
Other noncurrent assets	166	178
Total assets	634,793	306,302
Current liabilities
Accounts payable	6,139	6,247
Accrued expenses	18,814	33,480
Accrued rebates, returns and discounts	171,886	157,549
Current portion of term notes payable	46,859	3,833
Current portion of operating lease liabilities	676	656
Total current liabilities	244,374	201,765
Term notes payable, net of current portion	145,711	7,667
Convertible senior notes	94,383
Operating lease liabilities, net of current portion	9,262	9,438
Total liabilities	493,730	218,870
Commitments and contingencies (see Note 14)
Shareholders' equity:
Preferred stock, $0.001 par value; authorized shares - 5,000,000 at March 31, 2020 and December 31, 2019; issued and outstanding shares - none at March 31, 2020 and December 31, 2019
Common stock, $0.001 par value; authorized shares - 100,000,000 at March 31, 2020 and December 31, 2019; issued and outstanding shares - 34,306,040 at March 31, 2020 and 33,678,840 at December 31, 2019	34	34
Additional paid-in capital	500,478	447,297
Accumulated deficit	(359,449)	(359,899)
Total shareholders' equity	141,063	87,432
Total liabilities and shareholders' equity	$ 634,793	$ 306,302

CONDENSED CONDENSED CONSOLIDA_2

CONDENSED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
CONDENSED CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	100,000,000	100,000,000
Common stock, issued shares	34,306,040	33,678,840
Common stock, outstanding shares	34,306,040	33,678,840

CONDENSED CONDENSED CONSOLIDA_3

CONDENSED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues
Product revenues, net	$ 76,511	$ 74,516
Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)	27,229	45,476
Intangible asset amortization	10,295	3,688
Total cost of products revenues	37,524	49,164
Gross profit	38,987	25,352
Operating expenses
Research and development	2,666	2,992
Selling, general and administrative	31,260	32,352
Total costs and expenses	33,926	35,344
Income (loss) from operations	5,061	(9,992)
Interest expense	(4,823)	(234)
Interest income	212	526
Net income (loss)	$ 450	$ (9,700)
Earnings (loss) per share - basic (in dollars per share)	$ 0.01	$ (0.29)
Weighted-average shares - basic (in shares)	34,100,688	33,331,917
Earnings (loss) per share - diluted (in dollars per share)	$ 0.01	$ (0.29)
Weighted-average shares - diluted (in shares)	35,069,693	33,331,917

CONDENSED CONDENSED CONSOLIDA_4

CONDENSED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Operating activities
Net income (loss)	$ 450	$ (9,700)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Amortization expense	10,295	3,688	$ 14,752
Depreciation expense	198	184
Stock-based compensation expense	4,951	4,263
Non-cash lease expense	18	114
Non-cash interest expense for amortization of debt discount and issuance costs	1,336
Changes in operating assets and liabilities:
Accounts receivable	(12,474)	(7,193)
Inventory	(6,714)	(924)
Prepaid expenses and other assets	(2,990)	76
Accounts payable	(108)	1,583
Accrued expenses	(15,968)	(8,263)
Accrued rebates, returns and discounts	14,337	7,545
Operating lease assets and liabilities		734
Other long-term liabilities		(676)
Net cash used in operating activities	(6,669)	(8,569)
Investing activities
Purchase of intangible asset	(366,811)
Purchases of property and equipment	(836)	(3,323)
Net cash used in investing activities	(367,647)	(3,323)
Financing activities
Proceeds from issuances of common stock from employee stock purchase plans	357	444
Proceeds from the exercise of stock options	4,454	213
Payments made for employee restricted stock tax withholdings	(1,358)	(488)
Proceeds from issuance of term note, net of issuance costs of $2,200	192,373
Proceeds from convertible senior notes, net of issuance costs of $4,956	138,794
Repayment of term loan	(11,500)
Net cash provided by financing activities	323,120	169
Net decrease in cash, cash equivalents and restricted cash	(51,196)	(11,723)
Cash, cash equivalents and restricted cash at beginning of period	170,019	146,633	146,633
Cash, cash equivalents and restricted cash at end of period	118,823	134,910	170,019
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents				$ 116,178	$ 170,019	$ 134,910
Restricted cash				2,645
Total cash, cash equivalents and restricted cash	118,823	134,910	$ 146,633	$ 118,823	$ 170,019	$ 134,910
Supplemental disclosure of cash flow information
Cash paid for interest	3,456	178
Supplemental disclosure of non-cash activities
Acquisition of property and equipment in accounts payable and accrued expenses	392	810
Asset acquisition transaction costs in accounts payable and accrued expenses	1,415
Accrued royalties discharged upon closing of asset acquisition	1,145
Inventory used in the construction and installation of property and equipment	394	0
Term notes issuance costs in accounts payable and accrued expenses	256
Convertible senior notes issuance costs in accounts payable and accrued expenses	$ 517
Receivable from stock option exercises in other current assets		33
Operating lease assets assumed		9,957
Operating lease liabilities assumed		$ 10,691

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Term Loan
Debt Instrument [Line Items]
Issuance costs	$ 2,200
Convertible senior notes
Debt Instrument [Line Items]
Issuance costs	$ 4,956

Nature of Business

Nature of Business	3 Months Ended
Nature of Business	Mar. 31, 2020
Nature of Business
Nature of Business	1. Nature of Business Collegium Pharmaceutical, Inc. (the “Company”) was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Stoughton, Massachusetts. The Company is a specialty pharmaceutical company committed to being the leader in responsible pain management. The Company’s first product, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone. In April 2016, the Food and Drug Administration (the “FDA”) approved the Company’s new drug application (“NDA”) for Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. In June 2016, the Company announced the commercial launch of Xtampza ER. The Company’s product portfolio also includes Nucynta ER and Nucynta IR (the “Nucynta Products”). In December 2017, the Company entered into a Commercialization Agreement (the “Nucynta Commercialization Agreement”) with Assertio Therapeutics, Inc. (formerly known as Depomed) (“Assertio”), pursuant to which the Company acquired the right to commercialize the Nucynta Products in the United States. The Company began shipping and recognizing product sales on the Nucynta Products on January 9, 2018 and began marketing the Nucynta Products in February 2018. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. Nucynta IR is an immediate-release formulation of tapentadol that is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. On February 6, 2020, the Company entered into an Asset Purchase Agreement with Assertio (the “Nucynta Purchase Agreement”), pursuant to which the Company agreed to acquire from Assertio certain assets related to the Nucynta Products (the “Nucynta Acquisition”), including the rights to the license from Grünenthal GmbH (“Grünenthal”), for an aggregate purchase price of $375,000 , subject to certain closing and post-closing adjustments as described in the Nucynta Purchase Agreement. On February 13, 2020, the Company closed the Nucynta Acquisition in accordance with the Nucynta Purchase Agreement. Upon closing, the Nucynta Commercialization Agreement was terminated, with the exception of certain provisions thereof which survived pursuant to the terms of the Nucynta Purchase Agreement, and the Company’s royalty payment obligations to Assertio thereunder ceased. Following the closing, the Company will pay royalties directly to Grünenthal at a rate of In March 2020, the World Health Organization declared the continued spread of a novel coronavirus (“COVID-19”) a pandemic. The pandemic has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. The Company periodically reviews its accounting estimates in light of changes in circumstances, facts and experience. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company expects the COVID-19 pandemic and actions taken to contain it to impact revenue (due to fewer new patients beginning therapy with the Company’s products) and decrease certain operating expenses, including travel and regulatory expenses associated with post-marketing trials that are delayed for 2020. The Company believes that the disruptions caused by COVID-19 will be temporary, but there remains substantial uncertainty as to when such disruptions will cease (or ease). The Company’s operations are subject to certain risks and uncertainties. The principal risks include inability to successfully commercialize products, changing market conditions for products and development of competing products, changing regulatory environment and reimbursement landscape, litigation related to opioid marketing and distribution practices, manufacture of adequate commercial inventory, inability to secure adequate supplies of active pharmaceutical ingredients, key personnel retention, protection of intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company. The Company believes that its cash and cash equivalents at March 31, 2020, together with expected cash inflows from the commercialization of its products, will enable the Company to fund its operating expenses, debt service and capital expenditure requirements under its current business plan for the foreseeable future.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2020
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of Collegium Pharmaceutical, Inc. (a Virginia corporation) as well as the accounts of Collegium Securities Corp. (a Massachusetts corporation), incorporated in December 2015, and Collegium NF, LLC (a Delaware limited liability company), organized in December 2017, both wholly owned subsidiaries requiring consolidation. The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to fairly present the financial position of the Company as of March 31, 2020, the results of operations for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the full year. The preparation of the condensed consolidated financial statements in accordance with GAAP requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues, costs and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. Estimates in the Company’s consolidated financial statements include revenue recognition, including the estimates of product returns, units prescribed, discounts and allowances related to commercial sales of products, estimates of useful lives with respect to intangible assets, accounting for stock based compensation, contingencies, impairment of intangible assets, and tax valuation reserves. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions. The consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Annual Report”). Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in the Company’s Annual Report. During the current interim period covered by this report, the Company assumed certain material assets and liabilities in connection with consummating the Nucynta Acquisition, in addition to the issuance of convertible notes and term notes that required a review for embedded derivatives. As a result, the Company adopted the following accounting policy: Embedded Derivatives The Company accounts for derivative financial instruments as either equity or liabilities in accordance with Accounting Standards Codification Topic 815, Derivatives and Hedging that, in accordance with ASC 815, are not clearly and closely related to the host instrument and represent derivatives that are required to be re-measured at fair value each reporting period. The Company determined that the estimated fair value of the derivatives at issuance and as of March 31, 2020 were not material based on a scenario-based cash flow model that uses unobservable inputs that reflect the Company’s own assumptions. Should the Company’s assessment of the probabilities around these scenarios change, including for changes in market conditions, there could be a change to the fair value. Other than the aforementioned changes, there have been no material changes in the Company’s significant accounting policies, other than the adoption of accounting pronouncements below, as compared to the significant accounting policies described in the Annual Report. Reclassifications The Company has reclassified certain amounts in its condensed consolidated statements of operations for the three months ended March 31, 2019 to conform to the 2020 presentation. Specifically, the Company disaggregated previously reported cost of product revenue of $49,164 into the captions Cost of product revenues (excluding intangible asset amortization) $45,476 and Intangible asset amortization $3,688. The reclassifications relate to the presentation of the Company’s gross profit and amortization expense and were made to provide the readers of the Company’s consolidated financial statements with additional insight into how the Company and its management view and evaluate its performance and profitability. This reclassification within the consolidated statements of operations for the three months ended March 31, 2019 had no impact on previously reported total consolidated revenues or consolidated results of operations. Recently Adopted Accounting Pronouncements New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. The Company adopted Accounting Standard Updated (“ASU”) 2016-13 , Financial Instruments – Credit Losses (ASC Topic 326): Measurement of Credit Losses on Financial Instruments, w In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting reference rates in connection with reference rate reform, the Company will prospectively apply the amendments of ASU 2020-04 and disclose the effect on its consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
Revenue from Contracts with Customers	Mar. 31, 2020
Revenue from Contracts with Customers
Revenue from Contracts with Customers	3. Revenue from Contracts with Customers The Company’s revenue to date is from sales of the Company’s products, which are primarily sold to distributors (“customers”), which in turn sell the product to pharmacies for the treatment of patients (“end users”). Revenue Recognition In accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC Topic 606”), Performance Obligations The Company determined that performance obligations are satisfied and revenue is recognized when a customer takes control of the Company’s product, which occurs at a point in time. This generally occurs upon delivery of the products to customers, at which point the Company recognizes revenue and records accounts receivable, which represents the Company’s only contract asset. Payment is typically received 30 to 90 days after satisfaction of the Company’s performance obligations and generally does not have an effect on contract asset and contract liability balances. Under the practical expedients permitted by the rules of the adoption, the Company will expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the assets is one year or less. Transaction Price and Variable Consideration Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). The transaction price for product sales includes variable consideration related to sales deductions, including (1) rebates and incentives, including managed care rebates, government rebates, co-pay program incentives, and sales incentives and allowances; (2) product returns, including return estimates for both the Nucynta Products and Xtampza ER; and, (3) trade allowances and chargebacks, including fees for distribution service fees, prompt pay discounts, and chargebacks. The Company will estimate the amount of variable consideration that should be included in the transaction price under the expected value method for all sales deductions other than trade allowances, which are estimated under the most likely amount method. These provisions reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. In addition, the Company made a policy election to exclude from the measurement of the transaction price all taxes that are assessed by a governmental authority that are imposed on revenue-producing transactions. Provisions for rebates and incentives are based on the estimated amount of rebates and incentives to be claimed on the related sales from the period. As the Company’s rebates and incentives are based on products dispensed to patients, the Company is required to estimate the expected value of claims at the time of product delivery to distributors. Given that distributors sell the product to pharmacies, which in turn dispense the product to patients, claims can be submitted significantly after the related sales are recognized. The Company’s estimates of these claims are based on the historical experience of existing or similar programs, including current contractual and statutory requirements, specific known market events and trends, industry data, and estimated distribution channel inventory levels. Accruals and related reserves required for rebates and incentives are adjusted as new information becomes available, including actual claims. If actual results vary, the Company may need to adjust these estimates, which could have an effect on earnings in the period of the adjustment. Provisions for product returns are based on product-level historical trends, as well as relevant market events and other factors. For the Nucynta Products, estimates of product returns are primarily based on historical trends as the Nucynta Products have been commercially sold for a number of years. For Xtampza ER, since the product has only been commercially sold since June 2016, estimates of product returns are based on a combination of historical returns processed to date, taking into consideration the expiration date of the product upon delivery to customers, as well as forecasted customer buying patterns, shipment and prescription trends, channel inventory levels, and other specifically known market events and trends. Provisions for trade allowances and chargebacks are primarily based on customer-level contractual terms. Accruals and related reserves are adjusted as new information becomes available, which generally consists of actual trade allowances and chargebacks processed relating to sales recognized in the period. The amount of variable consideration that is included in the transaction price may be constrained and is included in net sales only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. In general, performance obligations do not include any estimated amounts of variable consideration that are constrained. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. The following tables summarize activity in each of the Company’s product revenue provision and allowance categories for the three months ended March 31, 2020 and 2019: Trade Rebates and Product Allowances and Three months ended March 31, 2020 Incentives (1) Returns (2) Chargebacks (3) Balance at December 31, 2019 $ 129,901 $ 27,648 $ 14,020 Provision related to current period sales 83,573 3,406 18,770 Changes in estimate related to prior period sales 1,131 — 49 Credits/payments made (73,075) (698) (18,625) Balance at March 31, 2020 $ 141,530 $ 30,356 $ 14,214 Trade Rebates and Product Allowances and Three months ended March 31, 2019 Incentives (1) Returns (2) Chargebacks (3) Balance at December 31, 2018 $ 129,318 $ 15,465 $ 14,841 Provision related to current period sales 65,881 4,992 15,658 Changes in estimate related to prior period sales (3,017) — — Credits/payments made (59,295) (1,016) (15,728) Balance at March 31, 2019 $ 132,887 $ 19,441 $ 14,771 (1) Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Condensed Balance Sheets. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets. (3) Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets. As of March 31, 2020, the Company did not have any transaction price allocated to remaining performance obligations and any costs to obtain contracts with customers, including pre-contract costs and set up costs, were immaterial. Disaggregation of Revenue The Company disaggregates its product revenue, net from contracts with customers, into the categories included in the table below. These categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors: Three months ended March 31, 2020 2019 Xtampza ER $ 31,507 $ 25,134 Nucynta Products 45,004 49,382 Total product revenues, net $ 76,511 $ 74,516 For the three months ended March 31, 2020, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $27,970 and $17,034, respectively. For the three months ended March 31, 2019, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $29,861 and $19,521, respectively.

License Agreements

License Agreements	3 Months Ended
License Agreements	Mar. 31, 2020
License Agreements
License Agreements	4. License Agreements The Company periodically enters into license agreements to develop and commercialize products. During the three months ended March 31, 2020 and 2019, the only products sold by the Company under a license agreement were the Nucynta Products. Prior to February 13, 2020, the Company sold the Nucynta Products pursuant to the rights licensed to it under the Nucynta Commercialization Agreement. Effective February 13, 2020, the Company sold the Nucynta Products pursuant to the rights licensed and acquired under the Nucynta Purchase Agreement, including certain intellectual property and manufacturing rights that it did not previously own under the Commercialization Agreement (see Note 8). Nucynta Commercialization Agreement On January 9, 2018 (the “Nucynta Commercialization Closing Date”), the Company consummated the transactions contemplated by the Nucynta Commercialization Agreement, pursuant to which Assertio agreed to grant a sublicense of certain of its intellectual property related to the Nucynta Products for commercialization in the United States. The Company began recording revenues from sales of the Nucynta Products on the Nucynta Commercialization Closing Date and began commercial promotion of the Nucynta Products in February 2018. Pursuant to the Nucynta Commercialization Agreement, the Company paid a one-time, non-refundable license fee of $10,000 to Assertio on the Nucynta Commercialization Closing Date, $6,223 for transferred inventory and $1,987 as reimbursement for prepaid expenses. The Company also assumed the existing liabilities of the Nucynta Products, including $22,660 related to sales of Nucynta Products that occurred prior to the Nucynta Commercialization Closing Date. The Nucynta Commercialization Agreement initially required the Company to pay a guaranteed minimum royalty of $135,000 per year through December 2021, payable in quarterly payments of $33,750, prorated in 2018 for the Nucynta Commercialization Closing Date, as well as a variable royalty based on annual net sales over $233,000. Beginning January 2022 and for each year of the Nucynta Commercialization Agreement term thereafter, the Company was required to pay a variable royalty on annual net sales of the Nucynta Products, but without a guaranteed minimum. Effective August 2018, the Company entered into a Second Amendment to the Nucynta Commercialization Agreement to clarify the mechanism for transferring title of products to be sold by the Company pursuant to the agreement and various related matters. The Second Amendment did not have an impact on the Company’s financial statements. Effective November 2018, the Company entered into the Third Amendment to the Nucynta Commercialization Agreement to adjust the royalty structure and termination clauses. Pursuant to the amended Nucynta Commercialization Agreement, the $135,000 guaranteed minimum annual royalties were eliminated, and the Company was no longer required to secure its royalty payment obligations with a standby letter of credit. Beginning on January 1, 2019 and thereafter, the Company was obligated to make royalty payments to Assertio conditional upon net sales and based on the following royalty structure for the period between January 1, 2019 and December 31, 2021: (i) (ii) (iii) (iv) (v) The Amendment did not modify the royalties payable on sales of the Nucynta Products on and after January 1, 2022, which remained as contemplated by the Nucynta Commercialization Agreement as in effect on January 9, 2018. In addition, prior to January 1, 2022, the Company was obligated to make royalty payments to Assertio, for ultimate payment to Grünenthal, at a rate of 14% of net sales of the Nucynta Products, subject to a guaranteed royalty of $34,000 when net sales were between $180,000 and $243,000. The Amendment further provided that if annual net sales of the Nucynta Products were less than $180,000 in any 12-month period through January 1, 2022, or if they are less than $170,000 in any 12-month period commencing on January 1, 2022, Assertio had the right to terminate the Nucynta Commercialization Agreement without penalty. The Amendment further provides that the Company did not have a right to terminate the Nucynta Commercialization Agreement prior to December 31, 2021. In connection with execution of the Third Amendment to the Nucynta Commercialization Agreement, the Company issued a warrant to Assertio to purchase 1,041,667 shares of common stock of the Company (the “Warrant”) at an exercise price of $19.20 per share. The Warrant will expire in November 2022 and includes customary adjustments for changes in the Company’s capitalization. Nucynta Purchase Agreement On February 6, 2020, the Company entered into the Nucynta Purchase Agreement with Assertio, pursuant to which the Company agreed to acquire from Assertio certain intellectual property and manufacturing rights related to the Nucynta Products for an aggregate purchase price of $375,000, subject to certain closing and post-closing adjustments as described in the Nucynta Purchase Agreement. In connection with the Nucynta Purchase Agreement, the Company also agreed to assume certain regulatory and supply chain contracts and obligations related to Nucynta Products. The Nucynta Purchase Agreement contains customary representations, warranties and covenants, and indemnification provisions subject to specified limitations. After the closing of the Nucynta Purchase Agreement, for the years 2020 and 2021, the Company will pay conditional royalties directly to Grünenthal at a rate of 14% of net sales of the Nucynta Products. This royalty payment obligation will replace the Company’s previous obligation to pay a royalty rate of 14% of net sales of the Nucynta Products to Grünenthal, subject to a guaranteed royalty of $34,000 when net sales are between $180,000 and $243,000. On February 13, 2020, the Company closed the Nucynta Acquisition in accordance with the Nucynta Purchase Agreement. Upon the closing, the Nucynta Commercialization Agreement was terminated, with the exception of certain provisions thereof which survived pursuant to the terms of the Nucynta Purchase Agreement, and the Company’s royalty payment obligations to Assertio thereunder ceased. The assets acquired, liabilities assumed, and equity interests issued by the Company in connection with the Nucynta Commercialization Agreement and Nucynta Purchase Agreement are further described in Note 8.

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2020
Earnings Per Share
Earnings Per Share	5. Earnings Per Share Basic net earnings per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock, plus potentially dilutive securities outstanding for the period, as determined in accordance with the treasury stock accounting method. Potentially dilutive securities outstanding include stock options, unvested restricted stock units, performance share units and warrants, but are only included to the extent that their addition is dilutive. The following table presents the computations of basic and dilutive earnings (loss) per common share: Three months ended March 31, 2020 2019 (1) Numerator: Net income (loss) $ 450 $ (9,700) Denominator: Weighted-average shares outstanding - basic 34,100,688 33,331,917 Effect of dilutive securities: Stock options 553,197 — Restricted stock units 305,341 — Performance share units 8,141 — Employee Stock Purchase Program 29,681 Warrants 72,645 — Weighted average shares outstanding - diluted 35,069,693 33,331,917 Earnings (loss) per share — basic $ 0.01 $ (0.29) Earnings (loss) per share — diluted $ 0.01 $ (0.29) (1) The Company incurred a net loss for the three months ended March 31, 2019, causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, which resulted in basic loss per share and dilutive loss per share being equivalent. The Company has the option to settle the conversion obligation for its convertible senior notes due in 2026 in cash, shares or any combination of the two. Since the Company’s intends to settle the principal amount of the convertible senior notes in cash, the Company used the treasury stock method for determining the potential dilution in the diluted earnings per share computation. For the three months ended March 31, 2020, the Company excluded 4,925,134 shares related to the convertible senior notes because their effect is anti-dilutive. The following table presents dilutive securities excluded from the calculation of diluted earnings per share due to their anti-dilutive effect: Three months ended March 31, 2020 2019 Stock options 2,262,400 4,156,580 Warrants — 1,041,667 Restricted stock units 57,834 893,462 Performance share units 267,498 99,400 Convertible senior notes 4,925,134 —

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
Fair Value of Financial Instruments	Mar. 31, 2020
Fair Value of Financial Instruments
Fair Value of Financial Instruments	6. Fair Value of Financial Instruments Disclosures of fair value information about financial instruments are required for financial instruments with respect to which it is practicable to estimate that value. Fair value measurements and disclosures describe the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows: Level 1 inputs: Quoted prices (unadjusted) in active markets for identical assets or liabilities Level 2 inputs: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3 inputs: Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the three months ended March 31, 2020 and 2019. The following tables present the Company’s financial instruments carried at fair value using the lowest level input applicable to each financial instrument at March 31, 2020 and December 31, 2019: Significant Quoted Prices other Significant in active observable unobservable markets inputs inputs Total (Level 1) (Level 2) (Level 3) March 31, 2020 Money market funds, included in cash equivalents $ 45,052 $ 45,052 $ — $ — December 31, 2019 Money market funds, included in cash equivalents $ 94,841 $ 94,841 $ — $ — The Company’s convertible senior notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. As of March 31, 2020, the convertible senior notes had a fair value of approximately $126,500 and a net carrying value of $94,383. The Company’s term notes fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. As of March 31, 2020, the carrying amounts of the cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued rebates, returns and discounts and operating lease liabilities approximated their estimated fair values.

Inventory

Inventory	3 Months Ended
Inventory	Mar. 31, 2020
Inventory
Inventory	7. Inventory Inventory as of March 31, 2020 and December 31, 2019 consisted of the following: As of March 31, As of December 31, 2020 2019 Raw materials $ 5,626 $ 795 Work in process 1,685 1,427 Finished goods 8,652 7,421 Total inventory $ 15,963 $ 9,643 The aggregate charges related to excess inventory for the three months ended March 31, 2020 and 2019 were immaterial. These expenses were recorded as a component of cost of product revenues. During the three months ended March 31, 2020 and 2019, inventory used in the construction and installation of property and equipment was $394 and $0, respectively.

Intangible Asset

Intangible Asset	3 Months Ended
Intangible Asset	Mar. 31, 2020
Intangible Asset
Intangible Asset	8. Intangible Asset As of March 31, 2020 and December 31, 2019, the Company’s only intangible asset (the “Nucynta Intangible Asset”) is related to the Nucynta Acquisition and Nucynta Commercialization Agreement. The gross carrying amount and accumulated amortization of the Nucynta Intangible Asset were as follows: As of March 31, As of December 31, 2020 2019 Gross carrying amount $ 521,170 $ 154,089 Accumulated amortization (134,881) (124,586) Intangible asset, net $ 386,289 $ 29,503 Nucynta Acquisition In February 2020, the Company entered into the Nucynta Purchase Agreement with Assertio, pursuant to which the Company acquired certain intellectual property and manufacturing rights related to the Nucynta Products, including U.S. commercialization rights, U.S. manufacturing rights, and inventory, for an aggregate purchase price of $375,000, subject to certain closing and post-closing adjustments. The Company also agreed to assume certain regulatory and supply chain contracts, and obligations related to Nucynta Products (see Note 4). In February 2020, the Company entered into a loan agreement (see Note 10) and issued convertible senior notes (see Note 11) to finance a portion of the purchase price paid pursuant to the Nucynta Purchase Agreement. The Company determined that the Nucynta Acquisition, closed in February 2020, should be accounted for as an asset acquisition in accordance with ASC Topic 805-50 because substantially all of the fair value of the gross assets acquired are concentrated in the right to commercialize the Nucynta Products in the U.S. The Company concluded that the fair value estimates of the assets surrendered was more clearly evident than the fair value of the assets received, and therefore followed a cost accumulation model to determine the consideration transferred in the asset acquisition. The consideration transferred in the asset acquisition was measured at cost, including transaction costs, assets transferred by the Company, and royalty obligations discharged by the seller. The table below represents the costs accumulated to acquire the commercial rights for the Nucynta Products based on the terms of the Nucynta Purchase Agreement, as amended: Acquisition consideration: Base purchase price $ 375,000 Cash paid for inventory 6,030 Transaction costs 6,297 Reduction for 2020 cash transferred to Assertio under the prior Nucynta Commercialization Agreement (1) (13,071) Reduction for accrued royalty obligation discharged upon closing (1) (1,145) Total acquisition consideration: $ 373,111 (1) Represents $14,216 total reduction to the base purchase price comprising of $13,071 of cash payments transferred to Assertio under the prior Nucynta Commercialization Agreement as well as a reduction for discharged pre-acquisition accrued royalties based on sales from January 1, 2020 through closing. The Company then allocated the consideration transferred to the individual assets acquired on a relative fair value basis as summarized in the table below: Assets acquired: Nucynta Intangible Asset $ 367,081 Inventory 6,030 Total consideration allocated to assets acquired: $ 373,111 The Company concluded that the consideration allocable to the Nucynta Intangible Asset for the additional intellectual property and manufacturing rights it acquired as part of the Nucynta Acquisition were incremental costs associated with the pre-existing intangible asset from the former Nucynta Commercialization Agreement, as such costs result in probable future economic benefits. Specifically, the additional intellectual property rights acquired in the Nucynta Acquisition enable the Company to eliminate royalty obligations otherwise payable to Assertio under the former Nucynta Commercialization Agreement. Nucynta Commercialization Agreement The Company determined that the Nucynta Commercialization Agreement, which closed in January 2018, should be accounted for as an asset acquisition in accordance with ASC Topic 805-50 , Under the original terms of the Nucynta Commercialization Agreement, the Company was obligated to make guaranteed annual minimum royalty payments of $537,000 to Assertio, which consisted of scheduled payments of $132,000 in 2018, $135,000 in 2019, $135,000 in 2020, and $135,000 in 2021. Due to the nature of the guaranteed minimum royalty payment obligation and the fact that it was required to be settled in cash, the Company determined that the future minimum royalty payments represented a liability that should be recorded at its fair value as of the Nucynta Commercialization Closing Date. The Company calculated the fair value of the future minimum royalty payments to be $482,300 using a discount rate of 5.7%. The discount rate was determined based on a review of observable market data relating to similar liabilities. The Company determined the $54,700 discount should be recognized as interest expense in the Statement of Operations using the effective interest method and over the repayment period from January 9, 2018 through December 2021. Prior to the Third Amendment to the Nucynta Commercialization Agreement in November 2018, the Company recognized interest expense of $19,281 relating to the minimum royalty payments and amortization expense of $107,662 related to the intangible asset Effective November 8, 2018 (the “Third Amendment Date”), the Company entered into the Third Amendment to the Nucynta Commercialization Agreement, which eliminated the guaranteed minimum royalty payment obligations for years 2019, 2020 and 2021. As a result, the Company remeasured the remaining contractual obligation as of the Third Amendment Date and recorded a reduction of the acquired intangible asset and obligation. As of December 31, 2018, the Company had paid all of the $132,000 of minimum royalty payment obligation owed under the Nucynta Commercialization Agreement for 2018. In connection with the Third Amendment to the Nucynta Commercialization Agreement, the Company issued a warrant to Assertio to purchase 1,041,667 shares of common stock of the Company at an exercise price of $19.20 per share. The Company estimated the fair value of the warrant on the date of issuance to be approximately $8,043 using the Black-Scholes option-pricing model. See Note 12 for further detail regarding the warrant issued to Assertio. A summary of the gross carrying amount, accumulated amortization, and net book value of the Nucynta Intangible Asset from the execution of the Nucynta Commercialization Agreement through period end are as follows: Gross Carrying Value Accumulated Amortization Net Book Value Intangible Asset, net Cost basis as of acquisition date $ 515,627 $ — $ 515,627 Amortization expense from acquisition date through Third Amendment Date — (107,662) (107,662) Adjustment due to the remeasurement of liability as of Third Amendment Date (369,581) — (369,581) Additional costs incurred as of Third Amendment Date (1) 8,043 — 8,043 Amortization expense from Amendment Date through fiscal year end — (2,172) (2,172) Balance as of December 31, 2018 $ 154,089 $ (109,834) $ 44,255 Amortization expense — (14,752) (14,752) Balance as of December 31, 2019 $ 154,089 $ (124,586) $ 29,503 Amortization expense through Nucynta Acquisition — (1,754) (1,754) Additional cost incurred from Nucynta Acquisition 367,081 — 367,081 Amortization expense from Nucynta Acquisition through period end — (8,541) (8,541) Balance as of March 31, 2020: $ 521,170 $ (134,881) $ 386,289 (1) Represents fair value of warrant issued in connection with the Amendment to the Nucynta Commercialization Agreement. Amortization The Company has been amortizing the Nucynta Intangible Asset over its useful life, which is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Company. The Company had initially determined that the useful life for the intangible asset was approximately 4.0 years from the closing date of the Nucynta Commercialization Agreement, January 9, 2018 on the basis of the majority of the cash flows expected to be realized for future product sales under the Nucynta Commercialization Agreement. The Nucynta Acquisition significantly impacted the timing and amount of future cash inflows from the sales of the Nucynta Products, and, therefore, the Company considered it to be a triggering event to remeasure the expected useful life of the Nucynta Intangible Asset. The Company determined that the useful life for the Nucynta Intangible Asset was approximately 5.9 years from the Closing Date of the Nucynta Acquisition and accordingly, the intangible asset will be amortized prospectively over its revised useful life. The Company will recognize amortization expense as a component of cost of product revenues in the Condensed Consolidated Statement of Operations on a straight-line basis over its useful life as it approximates the period of economic benefits expected to be realized from future cash inflows from sales of the Nucynta Products. Prior to the Nucynta Acquisition, the Company had recognized $126,340 of amortization expense related to the Nucynta Intangible Asset. As the accumulated cost basis of the Nucynta Intangible Asset was increased with the Nucynta Acquisition, the Company will continue to prospectively amortize the resulting net intangible asset on a straight-line basis over the remaining useful life. The following table presents amortization expense recognized for the thr ee months ended March 31, 2020 and 2019: Three months ended March 31, 2020 2019 Nucynta amortization expense included in cost of product revenues $ 10,295 $ 3,688 As of March 31, 2020, the remaining amortization period is approximately 5.8 years and the remaining estimated amortization for 2020, 2021, 2022, 2023, 2024 and 2025 is expected to be $50,385 , $67,181 , $67,181 , $67,181 , $67,181 and $67,180 , respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
Accrued Expenses	Mar. 31, 2020
Accrued Expenses
Accrued Expenses	9. Accrued Expenses Accrued expenses as of March 31, 2020 and December 31, 2019 consisted of the following: As of March 31, As of December 31, 2020 2019 Accrued royalties $ 6,301 $ 21,893 Accrued product taxes and fees 3,541 — Accrued bonuses 1,198 4,047 Accrued incentive compensation 1,522 1,650 Accrued payroll and related benefits 2,260 1,154 Accrued sales and marketing 805 775 Accrued interest 503 473 Accrued audit and legal 823 308 Accrued inventory 267 — Accrued other operating costs 1,594 3,180 Total accrued expenses $ 18,814 $ 33,480

Term Notes Payable

Term Notes Payable	3 Months Ended
Term Notes Payable	Mar. 31, 2020
Term Notes Payable
Term Notes Payable	10. Term Notes Payable Pharmakon Term Notes On February 6, 2020, in connection with the execution of the Nucynta Purchase Agreement, the Company, together with its subsidiary, Collegium Securities Corporation, entered into a Loan Agreement (the “Loan Agreement”) with BioPharma Credit PLC, as collateral agent and lender, and BioPharma Credit Investments V (Master) LP, as lender (collectively “Pharmakon”). The Loan Agreement provides for a $200,000 secured term loan (the “term notes”), the proceeds of which were used to finance a portion of the purchase price paid pursuant to the Nucynta Purchase Agreement. O n February 13, 2020 , the Company received the net proceeds. The term notes bear interest at a rate based upon the three-month LIBOR rate, subject to a LIBOR floor of 2.0%, plus a margin of 7.5% per annum, payable quarterly in arrears. The Company is required to repay the term notes by making equal quarterly payments of principal beginning in the first quarter immediately following the third month anniversary of the Closing Date. The term notes will mature on the calendar quarter end immediately following the 48-month anniversary of the Closing Date and is guaranteed by the Company’s material domestic subsidiaries and also secured by substantially all of the Company’s material assets. On the Closing Date, the Company paid to Pharmakon a facility fee equal to 2.50% of the aggregate principal amount of the term notes, or $5,000, in addition to $427 of other expenses incurred by Pharmakon and reimbursed by the Company (together, the “discount”). Net proceeds of $194,573 were transferred to Assertio by Collegium as agent in partial satisfaction of the Nucynta Purchase Agreement. In addition, the Company capitalized $2,456 of term notes issuance costs, related to legal and advisory fees. The Loan Agreement permits voluntary prepayment at any time in whole or in part, subject to a prepayment premium. Except with respect to certain prepayments made with the proceeds from new equity issuances as described below, the prepayment premium is equal to 3.00% of the principal amount being prepaid prior to the second-year anniversary of the Closing Date, 2.00% of the principal amount being prepaid on or after the second-year anniversary, but on or prior to the third-year anniversary, of the Closing Date, and 1.00% of the principal amount being prepaid on or after the third-year anniversary of the Closing Date, but prior to the fourth-year anniversary of the Closing Date. The Loan Agreement also includes a make-whole premium if there is a voluntary prepayment, a prepayment due to a change in control or acceleration following an Event of Default on or prior to the second-year anniversary of the Closing Date in an amount equal to foregone interest from the date of prepayment through the second-year anniversary of the Closing Date. A change of control triggers a mandatory prepayment of the term notes. If any single voluntary prepayment of the Loan Agreement of less than or equal to $50,000 is made solely from the proceeds of an equity issuance by the Company prior to the second-year anniversary of the Closing Date a prepayment premium of 5.00% would apply, with no make-whole. The Loan Agreement contains certain covenants and obligations of the parties, including, without limitation, covenants that require the Company to maintain $200,000 in annual net sales and covenants that limit the Company’s ability to incur additional indebtedness or liens, make acquisitions or other investments or dispose of assets outside the ordinary course of business, restrictions which limit the Company’s ability pay dividends and restrictions of net assets of subsidiaries. The Loan Agreement also contains customary events of default, including payment defaults, breaches of covenants, change of control and a material adverse change default. Failure to comply with these covenants would constitute an event of default under the Loan Agreement, notwithstanding the Company’s ability to meet its debt service obligations. The Loan Agreement also includes various customary remedies for Pharmakon following an event of default, including the acceleration of repayment of outstanding amounts under the Loan Agreement and execution upon the collateral securing obligations under the Loan Agreement. Under certain circumstances, a default interest rate will apply on outstanding obligations during the occurrence and continuance of an event of default. As of March 31, 2020, the Company was in compliance with all of its covenants. In March 2020, the Company amended the term notes with Pharmakon to clarify the timing of the quarterly payments of principal. The amendment did not modify the Company’s borrowings, interest rates, or covenants. During the three months ended March 31, 2020, the Company recognized approximately $2,986 of interest expense related to the term notes. As of March 31, 2020, scheduled principal repayments under the term notes are as follows: Years ended December 31, Principal Payments 2020 $ 37,500 2021 50,000 2022 37,500 2023 50,000 2024 25,000 Total before unamortized discount and issuance costs $ 200,000 Less: unamortized discount and issuance costs (7,430) Total term notes $ 192,570 Silicon Valley Bank Term Loan Facility From August 2012 until January 2020, the Company maintained a term loan facility with Silicon Valley Bank (“SVB”), which was amended in connection with, and as a condition to, consummation of the transactions contemplated by the Nucynta Commercialization Agreement. Under the amended term loan (“Consent and Amendment”), the Company had a term loan facility in an amount of $11.5 million, which replaced the Company’s previously existing term loan facility. The proceeds of the Consent and Amendment were used to finance certain payment obligations under the Nucynta Commercialization Agreement and to repay the balance of the previously existing term loan. The Consent and Amendment bore interest at a rate per annum of 0.75% above the prime rate (as defined in the Consent and Amendment). The Company was eligible to repay the Consent and Amendment in equal consecutive monthly installments of principal plus monthly payments of accrued interest, commencing in January 2020. In January 2020, the Company prepaid the outstanding principal and accrued interest on the Consent and Amendment along with the required prepayment fees. The loss on extinguishment of the term loan was immaterial and was recorded as a component of interest expense.

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
Convertible Senior Notes	Mar. 31, 2020
Convertible Senior Notes
Convertible Senior Notes	11. Convertible Senior Notes On February 13, 2020, the Company issued 2.625% convertible senior notes due in 2026 (the “convertible notes”) in the aggregate principal amount of $143,750, in a public offering registered under the Securities Act of 1933, as amended. The convertible notes were issued in connection with funding the Nucynta Acquisition, and the proceeds of the convertible notes were used to finance a portion of the purchase price payable pursuant to the Nucynta Purchase Agreement. Some of the Company’s existing investors participated in the convertible notes offering. The Company may, at its option, settle the convertible notes in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. Accordingly, the Company separately accounted for the liability component (the “Liability Component”) and the embedded derivative conversion option (the “Equity Component”) of the convertible notes by allocating the proceeds between the Liability Component and the Equity Component. In connection with the issuance of the convertible notes, the Company incurred approximately $5,473 of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs between the Liability Component and the Equity Component based on the allocation of the proceeds. Of the total debt issuance costs, $1,773 was allocated to the Equity Component and recorded as a reduction to additional paid-in capital and $3,700 was allocated to the Liability Component and recorded as a debt discount of the convertible notes. The portion allocated to the Liability Component is amortized to interest expense using the effective interest method over six years. The convertible notes are the Company’s senior unsecured obligations and bear interest at a rate of 2.625% per year payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2020. Before August 15, 2025, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after August 15, 2025, noteholders may convert their notes at any time at their election until the close of business on the scheduled trading day immediately before the maturity date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election. The notes will mature on February 15, 2026, unless earlier repurchased, redeemed or converted. The initial conversion rate is 34.2618 shares of common stock per $1 principal amount of notes, which represents an initial conversion price of approximately $29.19 per share of common stock. The conversion rate and conversion price are subject to adjustment upon the occurrence of certain events. Holders of the convertible notes may convert all or any portion of their convertible notes, in multiples of $1 principal amount, at their option only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the ‘‘measurement period’’) in which the “trading price” per $1 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company’s common stock; (4) if the Company calls the convertible notes for redemption; or (5) at any time from, and including, August 15, 2025 until the close of business on the scheduled trading day immediately before the maturity date. As of March 31, 2020, none of the above circumstances had occurred and as such, the convertible notes could not have been converted. The Company may not redeem the convertible notes prior to February 15, 2023. On or after February 15, 2023, the Company may redeem the convertible notes, in whole and not in part, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on: (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. Calling any convertible note for redemption will constitute a make-whole fundamental change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that convertible note, if it is converted in connection with the redemption, will be increased in certain circumstances for a specified period of time. The convertible notes have customary default provisions, including (i) a default in the payment when due (whether at maturity, upon redemption or repurchase upon fundamental change or otherwise) of the principal of, or the redemption price or fundamental change repurchase price for, any note; (ii) a default for 30 days in the payment when due of interest on any note; (iii) a default in the Company’s obligation to convert a note in accordance with the indenture; (iv) a default with respect to the Company’s obligations under the indenture related to consolidations, mergers and asset sales; (v) certain payment or other defaults by the Company or certain subsidiaries with respect to mortgages, agreements or other instruments for indebtedness for money borrowed of at least $20,000 ; and (vi) certain events of bankruptcy, insolvency and reorganization with respect to the Company or any of its significant subsidiaries. The initial carrying amount of the Liability Component of $97,200 was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected the Company’s non-convertible borrowing rate for similar debt. The Equity Component of the Notes of $46,550 was recognized as a debt discount. The excess of the principal amount of the Liability Component over its carrying amount is amortized to interest expense using the effective interest method over six years. The Equity Component, which is included in the additional paid in capital portion of stockholders’ equity on the Company’s consolidated balance sheet, is not remeasured as long as it continues to meet the conditions for equity classification. As of March 31, 2020, the convertible notes outstanding consisted of the following: Liability component: Principal $ 143,750 Less: unamortized debt discount and issuance costs (49,367) Net carrying amount $ 94,383 Equity component, net of issuance costs of $1,773 $ 44,777 The Company determined the expected life of the convertible notes was equal to its six-year term. The effective interest rate on the Liability Component of the convertible notes was 10.31%. As of March 31, 2020, the “if-converted value” did not exceed the remaining principal amount of the convertible notes. The fair value of the convertible notes was determined based on data points other than quoted prices that are observable, either directly or indirectly, and has been classified as Level 2 within the fair value hierarchy. The fair value of the convertible notes, which differs from their carrying value, is influenced by market interest rates, the Company’s stock price and stock price volatility. The following table presents the total interest expense recognized related to the convertible notes during the three months ended March 31, 2020: Three months ended March 31, 2020 Contractual interest expense $ 503 Amortization of debt discount 818 Amortization of debt issuance costs 65 Total interest expense $ 1,386 As of March 31, 2020, the future minimum payments on the convertible notes were as follows: Years ended December 31, Future Minimum Payments 2020 $ 1,939 2021 3,826 2022 3,826 2023 3,826 2024 3,836 Thereafter 149,504 Total minimum payments $ 166,757 Less: interest (23,007) Less: unamortized debt discount and issuance costs (49,367) Convertible senior notes $ 94,383

Equity

Equity	3 Months Ended
Equity	Mar. 31, 2020
Equity
Equity	12. Equity The changes in shareholders’ equity for three months ended March 31, 2020 were as follows: Additional Total Common Stock Paid- In Accumulated Shareholders’ Shares Amount Capital Deficit Equity (Deficit) Balance, December 31, 2019 33,678,840 $ 34 $ 447,297 $ (359,899) $ 87,432 Exercise of common stock options 455,573 — 4,454 — 4,454 Issuance for employee stock purchase plan 39,411 — 357 — 357 Vesting of restricted stock units ("RSUs") 195,280 — — — — Shares withheld for employee taxes upon vesting of RSUs (63,064) — (1,358) — (1,358) Stock-based compensation — — 4,951 — 4,951 Equity component of 2020 Convertible Notes, net of issuance costs of $1,773 — — 44,777 — 44,777 Net income — — — 450 450 Balance, March 31, 2020 34,306,040 $ 34 $ 500,478 $ (359,449) $ 141,063 The changes in shareholders’ equity for three months ended March 31, 2019 were as follows: Additional Total Common Stock Paid- In Accumulated Shareholders’ Shares Amount Capital Deficit Equity (Deficit) Balance, December 31, 2018 33,265,629 $ 33 $ 428,729 $ (337,177) $ 91,585 Exercise of common stock options 18,693 — 246 — 246 Issuance for employee stock purchase plan 32,826 — 444 — 444 Vesting of RSUs 101,483 — — — — Shares withheld for employee taxes upon vesting of RSUs (33,503) — (488) — (488) Stock-based compensation — — 4,263 — 4,263 Net loss — — — (9,700) (9,700) Balance, March 31, 2019 33,385,128 $ 33 $ 433,194 $ (346,877) $ 86,350 Warrants As of March 31, 2020, the warrant issued to Assertio in November 2018 was the Company’s only outstanding warrant. In connection with the Third Amendment to the Nucynta Commercialization Agreement, the Company issued a warrant to Assertio to purchase 1,041,667 shares of common stock of the Company at an exercise price of $19.20 per share. The terms of the warrant are fixed, with the exception of customary adjustments for changes in the Company’s capitalization. The warrant may only be settled with the issuance of shares of common stock upon exercise and will expire in November 2022. The Company has recorded the relative fair value of the warrant as a component of equity interest issued by the Company as consideration transferred in the cost accumulation model for the asset acquisition. The Company estimated the fair value of the warrant on the date of issuance to be approximately $8,043 using the Black-Scholes option-pricing model. The Company concluded that the warrant met the definition of an equity instrument and was recorded as a component of additional paid-in capital in the Company’s Condensed Consolidated Balance Sheet as of the issuance date.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
Stock-based Compensation	Mar. 31, 2020
Stock-based Compensation
Stock-based Compensation	13. Stock-based Compensation A summary of the Company’s stock-based compensation expense included in the Condensed Consolidated Statements of Operations are as follows: Three months ended March 31, 2020 2019 Research and development expenses $ 770 $ 567 Selling, general and administrative expenses 4,181 3,696 Total stock-based compensation expense $ 4,951 $ 4,263 At March 31, 2020, there was approximately $48,713 of unrecognized compensation expense related to unvested options, restricted stock units and performance stock units, which is expected to be recognized as expense over a weighted average period of approximately 3.0 years. Performance Share Units, Restricted Stock Units and Stock Options In May 2015, the Company adopted the Amended and Restated 2014 Stock Incentive Plan (the “Plan”), under which an aggregate of 2,700,000 shares of common stock were authorized for issuance to employees, officers, directors, consultants and advisors of the Company, plus an annual increase on the first day of each fiscal year until the expiration of the Plan equal to 4% of the total number of outstanding shares of common stock on December 31 st st Performance Share Units The Company periodically grants performance share units (“PSUs”) to certain members of the Company's senior management team. PSUs vest subject to the satisfaction of annual and cumulative performance and/or market conditions established by the Compensation Committee. In January 2019, the Company granted PSUs with performance conditions related to 2019, 2020, 2021 and three-year cumulative revenue goals for Xtampza ER. The PSUs will vest following a three-year performance period, subject to the satisfaction of the performance criteria and the executive’s continued employment through the performance period. PSUs may vest in a range between 0% and 200%, based on the satisfaction of performance criteria, and no shares will be issued if the minimum applicable performance metric is not achieved. The Company recognizes compensation expense ratably over the required service period based on its estimate of the number of shares that will vest based upon the probability of achieving the performance metrics. If there is a change in the estimate of the number of shares that are likely to vest, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. In February 2020, the Company additionally granted PSUs with performance criteria related to the relative ranking of the total stockholder return (“TSR”) of the Company’s common stock in 2020, 2021, 2022 and the cumulative three-year performance period return relative to the TSR of certain peer companies within the S&P Pharmaceutical Select Industry Index. TSR will be measured based on the 30-day average stock price on the first day of each period compared to the 30-day average stock price on the last day of each period. The 2020, 2021, and 2022 PSUs will vest annually, subject to the satisfaction of the performance criteria and the executive’s continued employment through the performance period. The cumulative PSUs will vest following the A summary of the Company’s PSUs activity for the three months ended March 31, 2020 and related information is as follows: Weighted-Average Shares Grant Date Fair Value Outstanding at December 31, 2019 99,400 $ 15.90 Granted 187,978 28.49 Vested — — Forfeited — — Performance adjustment (4,155) 15.90 Outstanding at March 31, 2020 283,223 $ 24.26 The number of PSUs awarded represents the target number of shares of common stock that may be earned; however, the actual number of shares earned may vary based on the satisfaction of performance criteria. For the three months ended March 31, 2020 and 2019, the stock-based compensation expense for PSUs was $397 and $15, respectively. Restricted Stock Units A summary of the Company’s restricted stock units activity for the three months ended March 31, 2020 and related information is as follows: Weighted-Average Shares Grant Date Fair Value Outstanding at December 31, 2019 849,679 $ 17.10 Granted 725,422 21.34 Vested (195,280) 17.83 Forfeited (7,263) 17.63 Outstanding at March 31, 2020 1,372,558 $ 19.23 The Company’s restricted stock units generally vest ratably over a four-year period of service. Stock Options A summary of the Company’s stock option activity for the three months ended March 31, 2020 and related information is as follows: Weighted- Weighted- Average Average Remaining Aggregate Exercise Price Contractual Intrinsic Shares per Share Term (in years) Value Outstanding at December 31, 2019 3,955,887 $ 16.00 7.5 $ 21,257 Granted 574,783 21.39 Exercised (455,573) 9.78 Cancelled (40,883) 19.36 Outstanding at March 31, 2020 4,034,214 $ 17.44 7.8 $ 5,904 Exercisable at March 31, 2020 1,916,510 $ 16.55 6.7 $ 3,550 The Company’s stock options generally vest ratably over a four-year period of service and have a ten-year contractual life. Upon termination, vested stock options are generally exercisable between one Three months ended March 31, 2020 2019 Risk-free interest rate 1.5 % 2.6 % Volatility 65.5 % 63.3 % Expected term (years) 6.1 6.1 Expected dividend yield — % — % Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan allows employees to purchase shares of the Company’s common stock. The purchase price is equal to 85% of the lower of the closing price of the Company’s common stock on (1) the first day of the purchase period or (2) the last day of the purchase period. During the three months ended March 31, 2020, 39,411 shares of common stock were purchased for total proceeds of $357. During the three months ended March 31, 2019, 32,826 shares of common stock were purchased for total proceeds of $444. The expense for the three months ended March 31, 2020 and 2019 was $79 and $100, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies Legal Proceedings From time to time, the Company may face legal claims or actions in the normal course of business. Except as disclosed below, the Company is not currently a party to any litigation and, accordingly, does not have any amounts recorded for any litigation related matters. Xtampza ER Litigation The Company filed the NDA for Xtampza ER as a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), in this case Oxycontin. The 505(b)(2) process requires that the Company certifies to the FDA and notify Purdue Pharma, L.P (“Purdue”), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for Oxycontin in the Orange Book, or that the patents are invalid. The Company made such certification and provided such notice on February 11, 2015 and such certification documented why Xtampza ER does not infringe any of the 11 Orange Book listed patents for Oxycontin, five of which have been invalidated in court proceedings. Under the Hatch-Waxman Act of 1984, Purdue had the option to sue the Company for infringement and receive a stay of up to 30 months before the FDA could issue a final approval for Xtampza ER, unless the stay was earlier terminated. Purdue exercised its option and elected to sue the Company for infringement in the District of Delaware on March 24, 2015 asserting infringement of three of Purdue’s Orange Book-listed patents (Patent Nos. 7,674,799, 7,674,800, and 7,683,072) and a non-Orange Book-listed patent (Patent No. 8,652,497), and accordingly, received a 30-month stay of FDA approval. The Delaware court transferred the case to the District of Massachusetts. After the Company filed a partial motion for judgment on the pleadings relating to the Orange Book-listed patents, the District Court of Massachusetts ordered judgment in the Company’s favor on those three patents, and dismissed the claims asserting infringement of those patents with prejudice. Upon dismissal of those claims, the 30-month stay of FDA approval was lifted. As a result, the Company was able to obtain final approval for Xtampza ER and launch the product commercially. In November 2015, Purdue filed a follow-on suit asserting infringement of another patent, Patent No. 9,073,933, which was late-listed in the Orange Book and therefore could not trigger any stay of FDA approval. In June 2016, Purdue filed another follow-on suit asserting infringement of another non-Orange Book listed patent, Patent No. 9,155,717. In April 2017, Purdue filed another follow-on suit asserting infringement of another patent, Patent No. 9,522,919, which was late-listed in the Orange Book and therefore could not trigger any stay of FDA approval. Then, in September 2017, Purdue filed another follow-on suit asserting infringement of another non-Orange Book listed patent, Patent No. 9,693,961. On March 13, 2018, the Company filed a Petition for Post-Grant Review (“PGR”) of the ʼ961 patent with the Patent Trial and Appeal Board (“PTAB”). The PGR argues that the ʼ961 patent is invalid for lack of a written description, for lack of enablement, for indefiniteness, and as being anticipated by prior art. Purdue filed its Patent Owner Preliminary Response on July 10, 2018. The PTAB entered an order to institute post-grant review of all claims of the ’961 patent on October 4, 2018, upon a finding that it is more likely than not that the claims of the ʼ961 patent are unpatentable. Purdue filed its Patent Owner Response on January 30, 2019. The Company filed its reply on April 12, 2019, and Purdue filed a sur-reply on May 10, 2019. The PTAB held oral argument on the proceedings on July 10, 2019 and was scheduled to issue a decision on the patentability of the ʼ961 patent by no later than October 4, 2019. On September 15, 2019, Purdue commenced a voluntary case under chapter 11 of title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York. On September 24, 2019, Purdue gave the PTAB notice of its bankruptcy filing and sought the imposition of an automatic stay of the PGR proceedings. On October 2, 2019, the PTAB extended the one-year period for issuing its decision by up to six months. In October 2017, and in response to the filing of the Company’s Supplemental NDA (“sNDA”) seeking to update the drug abuse and dependence section of the Xtampza ER label, Purdue filed another suit asserting infringement of the ʼ933 and ʼ919 patents. The Company filed a motion to dismiss that action, and the Court granted its motion on January 16, 2018. The current suits have been consolidated by the District of Massachusetts, where Purdue asserted infringement of five patents: the ʼ497 patent, the ʼ933 patent, the ʼ717 patent, the ʼ919 patent, and the ʼ961 patent. The Court issued an order on September 28, 2018 in which it granted in part a motion for summary judgment filed by the Company, and in which the Court ruled that the ʼ497 and ʼ717 patents are not infringed by the Company. As a result, only the ʼ933, the ʼ919, and the ʼ961 patents remain in dispute. On October 16, 2018, the Company filed a motion to stay proceedings in the district court on the ‘961 patent pending the PGR. None of these suits are associated with any stay of FDA approval for Xtampza ER. Purdue has made a demand for monetary relief but has not quantified its alleged damages. Purdue has also requested a judgment of infringement, an adjustment of the effective date of FDA approval, and an injunction on the sale of the Company’s products accused of infringement. The Company has denied all claims and seeks a judgment that the patents are invalid and/or not infringed by the Company; the Company is also seeking a judgment that the case is exceptional, with an award to the Company of its attorneys’ fees for defending the case. A claim construction hearing was held on June 1, 2017. On November 21, 2017, the Court issued its claim construction ruling, construing certain claims of the ʼ933, ʼ497, and ʼ717 patents. No trial date has been scheduled. On September 18, 2019, Purdue gave the Court notice of its bankruptcy filing and sought the imposition of an automatic stay of the proceedings. On September 20, 2019, the matter was stayed pending further order of the Court. Once the stay is lifted, the Company plans to defend this case vigorously. At this stage, the Company is unable to evaluate the likelihood of an unfavorable outcome or estimate the amount or range of potential loss, if any. Nucynta Litigation On February 7, 2018, Purdue filed a patent infringement suit against the Company in the District of Delaware. Specifically, Purdue argues that the Company’s sale of immediate-release and extended-release Nucynta infringes U.S. Patent Nos. 9,861,583, 9,867,784, and 9,872,836. Purdue has made a demand for monetary relief in its complaint but has not quantified its alleged damages. On December 6, 2018, the Company filed an Amended Answer asserting an affirmative defense for patent exhaustion. On December 10, 2018, the Court granted the parties’ stipulation for resolution of the Company’s affirmative defense of patent exhaustion and stayed the action, with the exception of briefing on and resolution of the Company’s Motion for Judgment on the Pleadings related to patent exhaustion and any discovery related to that Motion. Also, on December 10, 2018, the Company filed a Rule 12(c) Motion for Judgment on the Pleadings, arguing that the Purdue’s claims were barred by the doctrine of patent exhaustion. Purdue filed its response on January 11, 2019 and the Company filed a reply on January 25, 2019. On June 18, 2019, the court heard oral argument on the Company’s Rule 12(c) Motion for Judgment on the Pleadings. On June 19, 2019, the court issued an order stating that “judgment in Collegium’s favor is warranted under the doctrine of patent exhaustion to the extent Collegium’s alleged infringing activities resulted from sales that fall within the scope of that covenant.” The court explained, however, that based on the current record, it was not possible “to determine whether title of the Nucynta Products was transferred to Collegium” from sales authorized by Purdue’s covenant not to sue. The court ordered discovery on this issue and the case remained “stayed with the exception of discovery and briefing on and resolution of the Company’s anticipated motion for summary judgment based on patent exhaustion.” On September 19, 2019, Purdue gave the court notice of its bankruptcy filing and sought the imposition of an automatic stay of the proceedings. The Nucynta litigation is subject to the automatic bankruptcy stay. Pending resolution of the bankruptcy action, the Company plans to defend this case vigorously. At this stage, the Company is unable to evaluate the likelihood of an unfavorable outcome or estimate the amount or range of potential loss, if any. Teva Litigation The Company has fifteen patents listed in the FDA Orange Book as covering the Company’s abuse-deterrent product and methods of using it to treat patients: Patents Nos. 7,399,488; 7,771,707; 8,449,909; 8,557,291; 8,758,813; 8,840,928; 9,044,398; 9,248,195; 9,592,200; 9,682,075; 9,737,530, 9,763,883; 9,968,598; 10,004,729; and 10,188,644 (the “Orange Book Patents”). Teva Pharmaceuticals USA, Inc. (“Teva”) filed Notice Letters of Patent Certification against all of the fifteen listed Orange Book Patents alleging that they were invalid and/or not infringed by the proposed oxycodone products that are the subject of Teva’s Abbreviated New Drug Application (“ANDA”). On February 22, 2018—within the 45-day period that gives the Company a 30-month stay of FDA approval of Teva’s ANDA while the parties have an opportunity to litigate—the Company sued Teva in the District of Delaware on eleven of the Orange Book Patents. Teva responded to the Company’s complaint on May 14, 2018, alleging that the Orange Book Patents are invalid and are not infringed by Teva’s proposed ANDA products and asserting counterclaims of non-infringement and invalidity of the Orange Book Patents. The Company answered Teva’s counterclaims on June 4, 2018. The parties briefed claim construction and the court heard argument on April 12, 2019. On September 11, 2019, the Court issued a Report and Recommendation construing two of the six terms or sets of terms that are in dispute. The remaining terms will be addressed in one or more forthcoming Report and Recommendations. Fact discovery was scheduled to close on September 20, 2019 and expert discovery was scheduled to close on January 24, 2020. The Company filed a second lawsuit in the District of Delaware, asserting two additional Orange Book Patents, on November 30, 2018. Teva responded to the Company’s complaint on January 11, 2019, alleging that the asserted patents are invalid and are not infringed by Teva’s proposed ANDA products, and asserting counterclaims of non-infringement and invalidity of the asserted patents. The Company answered Teva’s counterclaims on February 1, 2019. The court consolidated the second suit with the first suit, and thus both suits are proceeding on the same schedule. The Company filed a third lawsuit in the District of Delaware, asserting one additional Orange Book Patent, on May 9, 2019. Teva responded to the Company’s complaint on June 6, 2019, alleging that the asserted patent is invalid and is not infringed by Teva’s proposed ANDA products, and asserting counterclaims of non-infringement and invalidity of the asserted patent. The Company answered Teva’s counterclaims on June 27, 2019. The parties filed a proposed Scheduling Order, which the Court entered on September 4, 2019. The parties have exchanged initial disclosures pursuant to that Order. On September 20, 2019, the parties jointly agreed to stay both litigations, which the Court so ordered. Once the stay is lifted, the Company plans to continue defending this case vigorously. Opioid Litigation On March 19, 2018, a lawsuit was filed by multiple local governments in the Circuit Court of Crittenden County, Arkansas, against the Company and other pharmaceutical manufacturers and distributors alleging a variety of claims related to opioid marketing and distribution practices. On January 29, 2019, the Company was dismissed from this litigation without prejudice. On March 21, 2018, the Company, along with other pharmaceutical manufacturers and distributors, was named in a class-action lawsuit filed in the Eastern District of Kentucky by a family practice clinic, on behalf of other similarly-situated healthcare providers. The action alleges violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”) relating to opioid marketing and distribution practices. On April 14, 2018, the lawsuit was conditionally transferred by the Judicial Panel on Multi-District Litigation to the federal Prescription Opiate Multi District Litigation (the “MDL”) in the Southern District of Ohio. On April 10, 2018, the conditional transfer was finalized and the lawsuit was docketed in the MDL on April 11, 2018. On May 4, 2018, the Company, along with other pharmaceutical manufacturers and distributors, were named in two lawsuits filed in the MDL by the Fiscal Court of Bourbon County, Kentucky and the Fiscal Court of Owen County, Kentucky, relating to opioid marketing and distribution practices. On July 11 and 12, 2018, the Company was named in four lawsuits filed in the MDL by a health system and various member hospitals. On September 26, 2018, the Company was named in two lawsuits filed in the MDL by the Fiscal Court of Lee County, Kentucky and the Fiscal Court of Wolfe County, Kentucky. On March 15, 2019, the plaintiffs in these MDL cases filed amended complaints which no longer name the Company as a defendant, effectively terminating these lawsuits as to the Company. On September 6, 2019, Triad Health Systems filed a class action lawsuit in the MDL on behalf of itself and similarly situated health care systems, generally alleging negligence, fraud, and violations of the RICO Act relating to opioid marketing and distribution practices, naming the Company and other pharmaceutical distributors and manufacturers. On October 18, 2019, three counties in Kentucky filed lawsuits in the MDL, naming the Company: the Fiscal Court of Casey County Kentucky; the Fiscal Court of Gallatin County Kentucky; and the Fiscal Court of Lewis County Kentucky. These lawsuits generally allege negligence, fraud, and violations of the RICO Act relating to opioid marketing and distribution practices. The Company was dismissed from these On January 11, 2019, the City of Portsmouth filed a lawsuit in Virginia Circuit Court against the Company and other pharmaceutical manufacturers and distributors. The lawsuit alleges a variety of claims related to opioid marketing and distribution practices including public nuisance, common law fraud, negligent misrepresentation, negligence, and violations of state consumer protection laws. On October 3, 2019, the City of Portsmouth case was transferred to the MDL. On March 15, 2019, the Company was named in a lawsuit in the MDL by the City of Paterson, New Jersey. The lawsuit alleges violations of fraud, public nuisance, negligent misrepresentation, and violations of state consumer protection laws, and seeks, generally, penalties and/or injunctive relief. In April 2019, the City of Norwich, Connecticut and the Town of Enfield, Connecticut filed lawsuits in Connecticut Superior Court. The lawsuits allege violations of fraud, public nuisance, negligent misrepresentation, and violations of state consumer protection laws. On June 28, 2019, both cases were transferred to the MDL. In October 2019, the Company was named in additional Connecticut lawsuits: the City of Middletown and the Town of Wethersfield. These cases were both also transferred to the MDL in July 2019. On January 15, 2020, the Company was named in a new lawsuit in Connecticut Superior Court, filed by the Town of Windham. This case was removed and transferred to the MDL in March 2020. On June 14, 2019, the City of Trenton filed a lawsuit in New Jersey Superior Court against the Company and other pharmaceutical manufacturers and distributors. The lawsuit alleges a variety of claims related to opioid marketing and distribution practices including public nuisance, common law fraud, negligent misrepresentation, negligence, and violations of state consumer protection laws and the New Jersey Drug Dealer Liability Act. On August 23, 2019, the case was removed to the District Court of New Jersey. The plaintiff filed an opposition to coordination and requested remand, but on December 18, 2019, the case was transferred to the MDL. Each of the lawsuits in the MDL naming the Company seeks, generally, penalties and injunctive relief. On May 29, 2018, a lawsuit was filed by Bucks County, Pennsylvania against the Company and other pharmaceutical manufacturers and on June 12, 2018, a lawsuit was filed by Clinton County, Pennsylvania, against the Company and other pharmaceutical manufacturers and distributors. On June 6, 2018, a lawsuit was filed by Mercer County, Pennsylvania, against the Company and other pharmaceutical manufacturers and distributors. These lawsuits allege claims related to opioid marketing and distribution, including negligence, fraud, unjust enrichment, public nuisance, and violations of state consumer protections laws. These cases have been consolidated for discovery purposes in the Delaware County Court of Common Pleas as part of a consolidated proceeding of similar lawsuits brought by numerous Pennsylvania counties against other pharmaceutical manufacturers and distributors. In March 2019, three additional cases were filed in Pennsylvania by two payor groups and Warminster Township. The Company has been dismissed from both of the payor group cases. In July 2019, the Company learned of additional lawsuits alleging similar claims which were filed by Warrington Township in the Bucks County Court of Common Pleas, and filed by the City of Lock Haven in the Clinton County Court of Common Pleas. The City of Lock Haven and the Warrington Township cases have been coordinated into the consolidated proceeding before the Delaware County Court of Common Pleas. On July 30, 2018, a lawsuit was filed by the City of Worcester, Massachusetts against the Company and other pharmaceutical manufacturers and distributors. The action alleges a variety of claims related to opioid marketing and distribution practices including public nuisance, common law fraud, negligent misrepresentation, negligence, violations of Mass Gen. Laws ch. 93A, Section 11, unjust enrichment and civil conspiracy. In February 2019, the City of Worcester case was transferred to the Business Litigation Session of the Superior Court. Additional lawsuits brought by the following cities and counties Massachusetts were filed between October 2018 and April 2019: City of Salem, City of Framingham, Town of Lynnfield, City of Springfield, City of Haverhill, City of Gloucester, Town of Canton, Town of Wakefield, City of Chicopee; Town of Natick; City of Cambridge, and Town of Randolph. Each of these additional lawsuits has been coordinated before the Business Litigation Session. The case brought by the City of Springfield was selected to advance for the purpose of motion practice, and defendants’ motions to dismiss were denied on January 3, 2020. The Company has answered the City of Cambridge complaint, and discovery in these coordinated cases is stayed, pending a May 28, 2020 case management conference where further scheduling and discovery will be addressed. The Company disputes the allegations in these lawsuits and intends to vigorously defend these actions. At this stage, the Company is unable to evaluate the likelihood of an unfavorable outcome or estimate the amount or range of potential loss, if any. Opioid-Related Request and Subpoenas The Company, like a number of other pharmaceutical companies, has received subpoenas or civil investigative demands related to opioid sales and marketing. The Company has received such subpoenas or civil investigative demands from the Offices of the Attorney General of each of Washington, New Hampshire, Massachusetts, and Maryland. The Company is currently cooperating with each of the foregoing states in their respective investigations.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2020
Summary of Significant Accounting Policies
Basis of Accounting	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of Collegium Pharmaceutical, Inc. (a Virginia corporation) as well as the accounts of Collegium Securities Corp. (a Massachusetts corporation), incorporated in December 2015, and Collegium NF, LLC (a Delaware limited liability company), organized in December 2017, both wholly owned subsidiaries requiring consolidation. The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to fairly present the financial position of the Company as of March 31, 2020, the results of operations for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the full year. The preparation of the condensed consolidated financial statements in accordance with GAAP requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues, costs and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. Estimates in the Company’s consolidated financial statements include revenue recognition, including the estimates of product returns, units prescribed, discounts and allowances related to commercial sales of products, estimates of useful lives with respect to intangible assets, accounting for stock based compensation, contingencies, impairment of intangible assets, and tax valuation reserves. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions. The consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Annual Report”).
Embedded Derivatives	Embedded Derivatives The Company accounts for derivative financial instruments as either equity or liabilities in accordance with Accounting Standards Codification Topic 815, Derivatives and Hedging that, in accordance with ASC 815, are not clearly and closely related to the host instrument and represent derivatives that are required to be re-measured at fair value each reporting period. The Company determined that the estimated fair value of the derivatives at issuance and as of March 31, 2020 were not material based on a scenario-based cash flow model that uses unobservable inputs that reflect the Company’s own assumptions. Should the Company’s assessment of the probabilities around these scenarios change, including for changes in market conditions, there could be a change to the fair value. Other than the aforementioned changes, there have been no material changes in the Company’s significant accounting policies, other than the adoption of accounting pronouncements below, as compared to the significant accounting policies described in the Annual Report.
Reclassifications	Reclassifications The Company has reclassified certain amounts in its condensed consolidated statements of operations for the three months ended March 31, 2019 to conform to the 2020 presentation. Specifically, the Company disaggregated previously reported cost of product revenue of $49,164 into the captions Cost of product revenues (excluding intangible asset amortization) $45,476 and Intangible asset amortization $3,688. The reclassifications relate to the presentation of the Company’s gross profit and amortization expense and were made to provide the readers of the Company’s consolidated financial statements with additional insight into how the Company and its management view and evaluate its performance and profitability. This reclassification within the consolidated statements of operations for the three months ended March 31, 2019 had no impact on previously reported total consolidated revenues or consolidated results of operations.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. The Company adopted Accounting Standard Updated (“ASU”) 2016-13 , Financial Instruments – Credit Losses (ASC Topic 326): Measurement of Credit Losses on Financial Instruments, w In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting reference rates in connection with reference rate reform, the Company will prospectively apply the amendments of ASU 2020-04 and disclose the effect on its consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
Revenue from Contracts with Customers (Tables)	Mar. 31, 2020
Revenue from Contracts with Customers
Summary of product revenue provision and allowance	Trade Rebates and Product Allowances and Three months ended March 31, 2020 Incentives (1) Returns (2) Chargebacks (3) Balance at December 31, 2019 $ 129,901 $ 27,648 $ 14,020 Provision related to current period sales 83,573 3,406 18,770 Changes in estimate related to prior period sales 1,131 — 49 Credits/payments made (73,075) (698) (18,625) Balance at March 31, 2020 $ 141,530 $ 30,356 $ 14,214 Trade Rebates and Product Allowances and Three months ended March 31, 2019 Incentives (1) Returns (2) Chargebacks (3) Balance at December 31, 2018 $ 129,318 $ 15,465 $ 14,841 Provision related to current period sales 65,881 4,992 15,658 Changes in estimate related to prior period sales (3,017) — — Credits/payments made (59,295) (1,016) (15,728) Balance at March 31, 2019 $ 132,887 $ 19,441 $ 14,771 (1) Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Condensed Balance Sheets. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets. (3) Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.
Schedule of disaggregation of revenue	Three months ended March 31, 2020 2019 Xtampza ER $ 31,507 $ 25,134 Nucynta Products 45,004 49,382 Total product revenues, net $ 76,511 $ 74,516

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Mar. 31, 2020
Earnings Per Share
Schedule of computations of basic and diluted net (loss) per share	Three months ended March 31, 2020 2019 (1) Numerator: Net income (loss) $ 450 $ (9,700) Denominator: Weighted-average shares outstanding - basic 34,100,688 33,331,917 Effect of dilutive securities: Stock options 553,197 — Restricted stock units 305,341 — Performance share units 8,141 — Employee Stock Purchase Program 29,681 Warrants 72,645 — Weighted average shares outstanding - diluted 35,069,693 33,331,917 Earnings (loss) per share — basic $ 0.01 $ (0.29) Earnings (loss) per share — diluted $ 0.01 $ (0.29) (1) The Company incurred a net loss for the three months ended March 31, 2019, causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, which resulted in basic loss per share and dilutive loss per share being equivalent.
Schedule of potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding	Three months ended March 31, 2020 2019 Stock options 2,262,400 4,156,580 Warrants — 1,041,667 Restricted stock units 57,834 893,462 Performance share units 267,498 99,400 Convertible senior notes 4,925,134 —

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
Fair Value of Financial Instruments (Tables)	Mar. 31, 2020
Fair Value of Financial Instruments
Schedule of financial instruments measured at fair value by level within fair value hierarchy	Significant Quoted Prices other Significant in active observable unobservable markets inputs inputs Total (Level 1) (Level 2) (Level 3) March 31, 2020 Money market funds, included in cash equivalents $ 45,052 $ 45,052 $ — $ — December 31, 2019 Money market funds, included in cash equivalents $ 94,841 $ 94,841 $ — $ —

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Mar. 31, 2020
Inventory
Schedule of Inventory	As of March 31, As of December 31, 2020 2019 Raw materials $ 5,626 $ 795 Work in process 1,685 1,427 Finished goods 8,652 7,421 Total inventory $ 15,963 $ 9,643

Intangible Asset (Tables)

Intangible Asset (Tables)	3 Months Ended
Intangible Asset (Tables)	Mar. 31, 2020
Intangible Asset
Carrying amount of Nucynta intangible	As of March 31, As of December 31, 2020 2019 Gross carrying amount $ 521,170 $ 154,089 Accumulated amortization (134,881) (124,586) Intangible asset, net $ 386,289 $ 29,503 Gross Carrying Value Accumulated Amortization Net Book Value Intangible Asset, net Cost basis as of acquisition date $ 515,627 $ — $ 515,627 Amortization expense from acquisition date through Third Amendment Date — (107,662) (107,662) Adjustment due to the remeasurement of liability as of Third Amendment Date (369,581) — (369,581) Additional costs incurred as of Third Amendment Date (1) 8,043 — 8,043 Amortization expense from Amendment Date through fiscal year end — (2,172) (2,172) Balance as of December 31, 2018 $ 154,089 $ (109,834) $ 44,255 Amortization expense — (14,752) (14,752) Balance as of December 31, 2019 $ 154,089 $ (124,586) $ 29,503 Amortization expense through Nucynta Acquisition — (1,754) (1,754) Additional cost incurred from Nucynta Acquisition 367,081 — 367,081 Amortization expense from Nucynta Acquisition through period end — (8,541) (8,541) Balance as of March 31, 2020: $ 521,170 $ (134,881) $ 386,289 (1) Represents fair value of warrant issued in connection with the Amendment to the Nucynta Commercialization Agreement.
Summary of costs included in acquired asset	Acquisition consideration: Base purchase price $ 375,000 Cash paid for inventory 6,030 Transaction costs 6,297 Reduction for 2020 cash transferred to Assertio under the prior Nucynta Commercialization Agreement (1) (13,071) Reduction for accrued royalty obligation discharged upon closing (1) (1,145) Total acquisition consideration: $ 373,111 (1) Represents $14,216 total reduction to the base purchase price comprising of $13,071 of cash payments transferred to Assertio under the prior Nucynta Commercialization Agreement as well as a reduction for discharged pre-acquisition accrued royalties based on sales from January 1, 2020 through closing. The Company then allocated the consideration transferred to the individual assets acquired on a relative fair value basis as summarized in the table below: Assets acquired: Nucynta Intangible Asset $ 367,081 Inventory 6,030 Total consideration allocated to assets acquired: $ 373,111
Summary of amortization expense	Three months ended March 31, 2020 2019 Nucynta amortization expense included in cost of product revenues $ 10,295 $ 3,688

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
Accrued Expenses (Tables)	Mar. 31, 2020
Accrued Expenses
Schedule of components of accrued expenses	As of March 31, As of December 31, 2020 2019 Accrued royalties $ 6,301 $ 21,893 Accrued product taxes and fees 3,541 — Accrued bonuses 1,198 4,047 Accrued incentive compensation 1,522 1,650 Accrued payroll and related benefits 2,260 1,154 Accrued sales and marketing 805 775 Accrued interest 503 473 Accrued audit and legal 823 308 Accrued inventory 267 — Accrued other operating costs 1,594 3,180 Total accrued expenses $ 18,814 $ 33,480

Term Notes Payable (Tables)

Term Notes Payable (Tables)	3 Months Ended
Term Notes Payable (Tables)	Mar. 31, 2020
Pharmakon Term Notes [Member]
Debt Instrument [Line Items]
Schedule of future payments under debt agreements	As of March 31, 2020, scheduled principal repayments under the term notes are as follows: Years ended December 31, Principal Payments 2020 $ 37,500 2021 50,000 2022 37,500 2023 50,000 2024 25,000 Total before unamortized discount and issuance costs $ 200,000 Less: unamortized discount and issuance costs (7,430) Total term notes $ 192,570

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
Convertible Senior Notes (Tables)	Mar. 31, 2020
Debt Instrument [Line Items]
Summary of convertible notes outstanding	Liability component: Principal $ 143,750 Less: unamortized debt discount and issuance costs (49,367) Net carrying amount $ 94,383 Equity component, net of issuance costs of $1,773 $ 44,777
Schedule of total interest expense recognized related to the convertible notes	Three months ended March 31, 2020 Contractual interest expense $ 503 Amortization of debt discount 818 Amortization of debt issuance costs 65 Total interest expense $ 1,386
Convertible senior notes
Debt Instrument [Line Items]
Schedule of principal repayments of debt	As of March 31, 2020, the future minimum payments on the convertible notes were as follows: Years ended December 31, Future Minimum Payments 2020 $ 1,939 2021 3,826 2022 3,826 2023 3,826 2024 3,836 Thereafter 149,504 Total minimum payments $ 166,757 Less: interest (23,007) Less: unamortized debt discount and issuance costs (49,367) Convertible senior notes $ 94,383

Equity (Tables)

Equity (Tables)	3 Months Ended
Equity (Tables)	Mar. 31, 2020
Equity
Summary of changes in Shareholders' Equity	The changes in shareholders’ equity for three months ended March 31, 2020 were as follows: Additional Total Common Stock Paid- In Accumulated Shareholders’ Shares Amount Capital Deficit Equity (Deficit) Balance, December 31, 2019 33,678,840 $ 34 $ 447,297 $ (359,899) $ 87,432 Exercise of common stock options 455,573 — 4,454 — 4,454 Issuance for employee stock purchase plan 39,411 — 357 — 357 Vesting of restricted stock units ("RSUs") 195,280 — — — — Shares withheld for employee taxes upon vesting of RSUs (63,064) — (1,358) — (1,358) Stock-based compensation — — 4,951 — 4,951 Equity component of 2020 Convertible Notes, net of issuance costs of $1,773 — — 44,777 — 44,777 Net income — — — 450 450 Balance, March 31, 2020 34,306,040 $ 34 $ 500,478 $ (359,449) $ 141,063 The changes in shareholders’ equity for three months ended March 31, 2019 were as follows: Additional Total Common Stock Paid- In Accumulated Shareholders’ Shares Amount Capital Deficit Equity (Deficit) Balance, December 31, 2018 33,265,629 $ 33 $ 428,729 $ (337,177) $ 91,585 Exercise of common stock options 18,693 — 246 — 246 Issuance for employee stock purchase plan 32,826 — 444 — 444 Vesting of RSUs 101,483 — — — — Shares withheld for employee taxes upon vesting of RSUs (33,503) — (488) — (488) Stock-based compensation — — 4,263 — 4,263 Net loss — — — (9,700) (9,700) Balance, March 31, 2019 33,385,128 $ 33 $ 433,194 $ (346,877) $ 86,350

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
Stock-based Compensation (Tables)	Mar. 31, 2020
Stock-based Compensation
Summary of performance share units activity	Weighted-Average Shares Grant Date Fair Value Outstanding at December 31, 2019 99,400 $ 15.90 Granted 187,978 28.49 Vested — — Forfeited — — Performance adjustment (4,155) 15.90 Outstanding at March 31, 2020 283,223 $ 24.26
Summary of restricted stock units activity	Weighted-Average Shares Grant Date Fair Value Outstanding at December 31, 2019 849,679 $ 17.10 Granted 725,422 21.34 Vested (195,280) 17.83 Forfeited (7,263) 17.63 Outstanding at March 31, 2020 1,372,558 $ 19.23
Summary of stock option activity	Weighted- Weighted- Average Average Remaining Aggregate Exercise Price Contractual Intrinsic Shares per Share Term (in years) Value Outstanding at December 31, 2019 3,955,887 $ 16.00 7.5 $ 21,257 Granted 574,783 21.39 Exercised (455,573) 9.78 Cancelled (40,883) 19.36 Outstanding at March 31, 2020 4,034,214 $ 17.44 7.8 $ 5,904 Exercisable at March 31, 2020 1,916,510 $ 16.55 6.7 $ 3,550
Summary of stock-based compensation	Three months ended March 31, 2020 2019 Research and development expenses $ 770 $ 567 Selling, general and administrative expenses 4,181 3,696 Total stock-based compensation expense $ 4,951 $ 4,263
Schedule of fair value assumption using Black-Scholes option-pricing model	Three months ended March 31, 2020 2019 Risk-free interest rate 1.5 % 2.6 % Volatility 65.5 % 63.3 % Expected term (years) 6.1 6.1 Expected dividend yield — % — %

Nature of Business (Details)

Nature of Business (Details) - Assertio - Nucynta Purchase Agreement - Nucynta Products $ in Thousands	Feb. 06, 2020USD ($)
Aggregate purchase price	$ 375,000
Royalty payment as percentage of annual net sales	14.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cost of product revenues	$ 37,524	$ 49,164
Cost of product revenues (excluding intangible asset amortization)	27,229	45,476
Intangible asset amortization	$ 10,295	3,688
Adjustment
Cost of product revenues		(49,164)
Cost of product revenues (excluding intangible asset amortization)		45,476
Intangible asset amortization		$ 3,688

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Narrative (Details)	3 Months Ended
Revenue from Contracts with Customers - Narrative (Details)	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Practical expedient incremental cost	true	true
Minimum
Disaggregation of Revenue [Line Items]
Term of payment received	30 days	30 days
Maximum
Disaggregation of Revenue [Line Items]
Term of payment received	90 days	90 days

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Transaction Price and Variable Consideration (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Rebates and Incentives
Allowance categories
Balance at beginning of the period	$ 129,901	$ 129,318
Provision related to current period sales	83,573	65,881
Changes in estimate related to prior period sales	1,131	(3,017)
Credits/payments made	(73,075)	(59,295)
Balance at end of the period	141,530	132,887
Product Returns
Allowance categories
Balance at beginning of the period	27,648	15,465
Provision related to current period sales	3,406	4,992
Credits/payments made	(698)	(1,016)
Balance at end of the period	30,356	19,441
Trade Allowances and Chargebacks
Allowance categories
Balance at beginning of the period	14,020	14,841
Provision related to current period sales	18,770	15,658
Changes in estimate related to prior period sales	49
Credits/payments made	(18,625)	(15,728)
Balance at end of the period	$ 14,214	$ 14,771

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue
Product revenues, net	$ 76,511	$ 74,516
Xtampza ER
Disaggregation of Revenue
Product revenues, net	31,507	25,134
Nucynta Products
Disaggregation of Revenue
Product revenues, net	45,004	49,382
Nucynta IR
Disaggregation of Revenue
Product revenues, net	27,970	29,861
Nucynta ER
Disaggregation of Revenue
Product revenues, net	$ 17,034	$ 19,521

License Agreements (Details)

License Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 06, 2020	Jan. 09, 2018	Nov. 30, 2018	Mar. 31, 2020	Mar. 31, 2019
License Agreements [Line Items]
License fee				$ 37,524	$ 49,164
Annual net sales				76,511	74,516
Nucynta Products
License Agreements [Line Items]
Annual net sales				$ 45,004	$ 49,382
Nucynta Commercialization Agreement \| Assertio
License Agreements [Line Items]
License fee		$ 10,000
Nucynta Commercialization Agreement \| Nucynta Products \| Assertio
License Agreements [Line Items]
Payment for inventory		6,223
Reimbursement for prepaid expenses		1,987
Liability relating to sales		22,660
Annual net sales		135,000
Quarterly royalty payable		33,750
Base annual net sales for variable royalty		$ 233,000
Third Amendment to the Commercialization Agreement
License Agreements [Line Items]
Number of shares that can be purchased			1,041,667
Exercise price of warrant			$ 19.20
Third Amendment to the Commercialization Agreement \| Nucynta Products
License Agreements [Line Items]
Minimum royalty payment eliminated			$ 135,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Maximum \| Any 12-month period through January 1, 2022
License Agreements [Line Items]
Net sales limit upon which Counterparty can terminate without penalty			180,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Maximum \| Any 12-month period commencing on January 1, 2022
License Agreements [Line Items]
Net sales limit upon which Counterparty can terminate without penalty			$ 170,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Sales Royalty Structure 1
License Agreements [Line Items]
Royalty payment as percentage of annual net sales			65.00%
Royalty payment limit between January 1, 2019 and December 31, 2021			$ 180,000
Collaborative Arrangement, Royalty Payment Limit			$ 180,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Sales Royalty Structure 2
License Agreements [Line Items]
Royalty payment as percentage of annual net sales			14.00%
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Sales Royalty Structure 3
License Agreements [Line Items]
Royalty payment as percentage of annual net sales			58.00%
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Sales Royalty Structure 4
License Agreements [Line Items]
Royalty payment as percentage of annual net sales			20.00%
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Sales Royalty Structure 5
License Agreements [Line Items]
Royalty payment as percentage of annual net sales			15.00%
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| prior to January 1, 2022
License Agreements [Line Items]
Royalty payment as percentage of annual net sales			14.00%
Royalty payment limit between January 1, 2019 and December 31, 2021			$ 34,000
Collaborative Arrangement, Royalty Payment Limit			34,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Minimum \| Sales Royalty Structure 2
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			180,000
Collaborative Arrangement, Royalty Payment Limit			180,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Minimum \| Sales Royalty Structure 3
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			210,000
Collaborative Arrangement, Royalty Payment Limit			210,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Minimum \| Sales Royalty Structure 4
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			233,000
Collaborative Arrangement, Royalty Payment Limit			233,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Minimum \| Sales Royalty Structure 5
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			258,000
Collaborative Arrangement, Royalty Payment Limit			258,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Minimum \| prior to January 1, 2022
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			180,000
Collaborative Arrangement, Royalty Payment Limit			180,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Maximum \| Sales Royalty Structure 2
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			210,000
Collaborative Arrangement, Royalty Payment Limit			210,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Maximum \| Sales Royalty Structure 3
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			233,000
Collaborative Arrangement, Royalty Payment Limit			233,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Maximum \| Sales Royalty Structure 4
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			258,000
Collaborative Arrangement, Royalty Payment Limit			258,000
Third Amendment to the Commercialization Agreement \| Nucynta Products \| Assertio \| Maximum \| prior to January 1, 2022
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021			243,000
Collaborative Arrangement, Royalty Payment Limit			$ 243,000
Nucynta Purchase Agreement \| Nucynta Products \| Assertio
License Agreements [Line Items]
Royalty payment as percentage of annual net sales	14.00%
Aggregate purchase price	$ 375,000
Guaranteed royalty	34,000
Nucynta Purchase Agreement \| Nucynta Products \| Assertio \| Minimum
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021	180,000
Collaborative Arrangement, Royalty Payment Limit	180,000
Nucynta Purchase Agreement \| Nucynta Products \| Assertio \| Maximum
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021	243,000
Collaborative Arrangement, Royalty Payment Limit	$ 243,000

Earnings Per Share - Computatio

Earnings Per Share - Computation of Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss per common share
Net income (loss)	$ 450	$ (9,700)
Weighted-average shares - basic (in shares)	34,100,688	33,331,917
Weighted-average shares - diluted (in shares)	35,069,693	33,331,917
Earnings (loss) per share - basic (in dollars per share)	$ 0.01	$ (0.29)
Earnings (loss) per share - diluted (in dollars per share)	$ 0.01	$ (0.29)
Stock options
Net loss per common share
Effect of dilutive securities	553,197
Restricted stock units
Net loss per common share
Effect of dilutive securities	305,341
Performance share units
Net loss per common share
Effect of dilutive securities	8,141
Employee Stock Purchase Program
Net loss per common share
Effect of dilutive securities	29,681
Warrants
Net loss per common share
Effect of dilutive securities	72,645

Earnings Per Share - Summary of

Earnings Per Share - Summary of Potentially Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock options
Anti-dilutive securities
Potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding	2,262,400	4,156,580
Warrants
Anti-dilutive securities
Potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding		1,041,667
Restricted stock units
Anti-dilutive securities
Potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding	57,834	893,462
Performance share units
Anti-dilutive securities
Potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding	267,498	99,400
Convertible senior notes
Anti-dilutive securities
Potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding	4,925,134

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Transfer of Assets From Level 1 to Level 2	$ 0	$ 0
Transfer of Assets From Level 2 to Level 1	0	0
Transfer of Liabilities From Level 1 to Level 2	0	0
Transfer of Liabilities From Level 2 to Level 1	0	0
Transfer of Assets Into Level 3	0	0
Transfer of Assets Out of Level 3	0	0
Transfer of Liabilities Into Level 3	0	0
Transfer of Liabilities Out of Level 3	0	$ 0
Convertible senior notes, fair value	126,500
Net carrying value	94,383
Money market funds
Cash equivalents	45,052		$ 94,841
Quoted Prices in active markets (Level 1) \| Money market funds
Cash equivalents	$ 45,052		$ 94,841

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	3 Months Ended
Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Inventory
Raw materials	$ 5,626		$ 795
Work in process	1,685		1,427
Finished goods	8,652		7,421
Total inventory	15,963		$ 9,643
Inventory used in the construction and installation of property and equipment	$ 394	$ 0

Intangible Assets - Gross Carry

Intangible Assets - Gross Carrying amount and Accumulated Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 09, 2018
Gross carrying amount	$ 521,170	$ 154,089
Accumulated amortization	(134,881)	(124,586)
Intangible assets, net	386,289	29,503
Nucynta Products
Gross carrying amount	521,170	154,089	$ 154,089	$ 515,627
Accumulated amortization	(134,881)	(124,586)	(109,834)
Intangible assets, net	$ 386,289	$ 29,503	$ 44,255

Intangible Assets - Costs Accum

Intangible Assets - Costs Accumulated to Acquire Intangible Asset and Consideration Transferred (Details) - Nucynta Products - USD ($) $ in Thousands	Feb. 06, 2020	Mar. 31, 2020
Acquisition consideration:
Base purchase price		$ 375,000
Cash paid for inventory		6,030
Transaction costs		6,297
Reduction for 2020 cash transferred to Assertio under the prior Nucynta Commercialization Agreement(1)		(13,071)
Reduction for accrued royalty obligation discharged upon closing(1)		(1,145)
Total acquisition consideration		373,111
Reduction to base purchase price		14,216
Consideration transferred to assets acquired:
Nucynta Intangible Asset		367,081
Inventory		6,030
Total consideration allocated to assets acquired		$ 373,111
Assertio \| Nucynta Purchase Agreement
Finite-Lived Intangible Assets [Line Items]
Aggregate purchase price	$ 375,000

Intangible Assets - Minimum Roy

Intangible Assets - Minimum Royalty Payments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2018	Nov. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Fair value of warrant	$ 8,043
Nucynta Commercialization Agreement
Finite-Lived Intangible Assets [Line Items]
Annual minimum royalty payments	537,000
2018	132,000
2019	135,000
2020	135,000
2021	135,000
Fair Value of future minimum royalty payments	$ 482,300
Discounted rate	5.70%
Interest expense recognized	$ 54,700
Interest expense recognized, relating to royalty payments, prior to third amendment	19,281
Amortization expense recognized prior to third amendment	$ 107,662
Third Amendment to the Commercialization Agreement
Finite-Lived Intangible Assets [Line Items]
Annual minimum royalty payments		$ 132,000
Common stock that may be purchased upon exercise of warrant (in shares)			1,041,667
Exercise price of warrant (in dollars per share)			$ 19.20

Intangible Assets - Gross car_2

Intangible Assets - Gross carrying amount, accumulated amortization, and net book value (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		10 Months Ended	12 Months Ended
	Feb. 06, 2020	Feb. 05, 2020	Mar. 31, 2020	Mar. 31, 2019	Nov. 07, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 08, 2018	Jan. 09, 2018
Gross carrying amount			$ 521,170			$ 154,089
Amortization expense			(10,295)	$ (3,688)		(14,752)
Accumulated amortization			(134,881)			(124,586)
Intangible assets, net			386,289			29,503
Nucynta Products
Gross carrying amount			521,170			154,089	$ 154,089		$ 515,627
Amortization expense					$ (107,662)		(2,172)
Accumulated amortization			(134,881)			(124,586)	(109,834)
Adjustment due to remeasurement of liability								$ (369,581)
Additional costs incurred								$ 8,043
Intangible assets, net			$ 386,289			$ 29,503	$ 44,255
Nucynta Purchase Agreement
Amortization expense	$ (8,541)	$ (1,754)
Additional costs incurred	$ 367,081

Intangible Assets - Amortizatio

Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Jan. 09, 2018	Mar. 31, 2020	Mar. 31, 2019	Nov. 07, 2018	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Useful life		5 years 9 months 18 days
Amortization expense recognized prior to third amendment		$ 126,340
Nucynta amortization expense included in cost of product revenues		10,295	$ 3,688		$ 14,752
2020		50,385
2021		67,181
2022		67,181
2023		67,181
2024		67,181
2025		$ 67,180
Nucynta Products
Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	5 years 10 months 24 days
Nucynta amortization expense included in cost of product revenues				$ 107,662		$ 2,172

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued Expenses
Accrued royalties	$ 6,301	$ 21,893
Accrued product taxes and fees	3,541
Accrued bonuses	1,198	4,047
Accrued incentive compensation	1,522	1,650
Accrued payroll and related benefits	2,260	1,154
Accrued sales and marketing	805	775
Accrued interest	503	473
Accrued audit and legal	823	308
Accrued inventory	267
Accrued other operating costs	1,594	3,180
Total accrued expenses	$ 18,814	$ 33,480

Term Notes Payable - Pharmakon

Term Notes Payable - Pharmakon (Details) - Pharmakon Term Notes [Member] - USD ($) $ in Thousands	Feb. 06, 2020	Mar. 31, 2020
Debt
Aggregate principal amount	$ 200,000
Margin rate	7.50%
Debt maturity	48 months
Facility fee (as a percent)	2.50%
Facility fee amount	$ 5,000
Debt issuance costs	427
Net proceeds	194,573
Issuance cost capitalized	2,456	$ 7,430
Threshold amount of single voluntary prepayment from equity proceeds	50,000
Threshold annual net sales to be maintained	$ 200,000
Interest expense		2,986
Future minimum payments
2020		37,500
2021		50,000
2022		37,500
2023		50,000
2024		25,000
Total, Gross		200,000
Total term notes		$ 192,570
Prepayment prior to the second-year anniversary
Debt
Prepayment premium percentage	3.00%
Prepayment on or after the second-year anniversary, but on or prior to the third-year anniversary
Debt
Prepayment premium percentage	2.00%
Prepayment on or after the third-year anniversary
Debt
Prepayment premium percentage	1.00%
Single voluntary prepayment of threshold amount prior to the second-year anniversary
Debt
Prepayment premium percentage	5.00%
LIBOR
Debt
Floor rate	2.00%

Term Notes Payable - Silicon Va

Term Notes Payable - Silicon Valley (Details) - Silicon Valley Bank Term Loan Facility $ in Millions	1 Months Ended
	Jan. 31, 2020USD ($)
Debt
Line of credit	$ 11.5
Prime
Debt
Margin rate	0.75%

Convertible Senior Notes - Narr

Convertible Senior Notes - Narrative (Details) $ / shares in Units, $ in Thousands	Feb. 13, 2020USD ($)D$ / shares	Mar. 31, 2020USD ($)D	Aug. 15, 2020
Debt
Equity component of transaction costs for 2020 Convertible Notes	$ 1,773	$ 1,773
Conversion of convertible debt after the calendar quarter ending on march 31, 2020
Debt
Amortization period of debt discount	6 years
Convertible senior notes
Debt
Interest rate (as a percent)	2.625%		2.625%
Aggregate principal amount	$ 143,750
Total debt issuance cost	5,473
Debt discount	$ 3,700
Amortization period of debt discount	6 years
Initial conversion rate	34.2618
Conversion, threshold percentage of stock price trigger \| $ / shares	$ 29.19
Consecutive business days \| D	5
Measurement period \| D	10
Threshold percentage to product of sale price of common stock and conversion rate	98.00%
Redemption, threshold percentage of stock price trigger	130.00%
Redemption, threshold trading days \| D	20
Redemption, threshold consecutive trading days \| D	30
Default period	30 days
Threshold amount of money borrowed	$ 20,000
Initial carrying amount of the Liability Component	97,200
Carrying amount of the Equity Component	$ 46,550
Convertible senior notes \| Conversion of convertible debt after the calendar quarter ending on march 31, 2020
Debt
Conversion, threshold percentage of stock price trigger		130.00%
Conversion, threshold trading days \| D		20
Conversion, threshold consecutive trading days \| D		30

Convertible Senior Notes - Outs

Convertible Senior Notes - Outstanding (Details) - USD ($) $ in Thousands	Feb. 13, 2020	Mar. 31, 2020
Debt
Net carrying amount		$ 94,383
Equity component of transaction costs for 2020 Convertible Notes	$ 1,773	1,773
Convertible senior notes
Debt
Principal		143,750
Less: unamortized debt discount and issuance costs		(49,367)
Net carrying amount		94,383
Equity component, net of issuance costs of $1,773		$ 44,777
Debt term		6 years
Effective interest rate		10.31%

Convertible Senior Notes - Inte

Convertible Senior Notes - Interest Expenses (Details) - Convertible senior notes $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Debt
Contractual interest expense	$ 503
Amortization of debt discount	818
Amortization of debt issuance costs	65
Total interest expense	$ 1,386

Convertible Senior Notes - Futu

Convertible Senior Notes - Future Minimum Payments (Details) $ in Thousands	Mar. 31, 2020USD ($)
Future minimum payments
Convertible senior notes	$ 94,383
Convertible senior notes
Future minimum payments
2020	1,939
2021	3,826
2022	3,826
2023	3,826
2024	3,836
Thereafter	149,504
Total minimum payments	166,757
Less: interest	(23,007)
Less: unamortized debt discount and issuance costs	(49,367)
Convertible senior notes	$ 94,383

Equity - Changes in Shareholder

Equity - Changes in Shareholders' Equity (Details) - USD ($) $ in Thousands	Feb. 13, 2020	Mar. 31, 2020	Mar. 31, 2019
Balance at beginning of period		$ 87,432	$ 91,585
Exercise of common stock options		4,454	246
Issuance for employee stock purchase plan		$ 357	$ 444
Issuance for employee stock purchase plan, shares		39,411	32,826
Shares withheld for employee taxes upon vesting of RSUs		$ (1,358)	$ (488)
Stock-based compensation		4,951	4,263
Equity component of 2020 Convertible Notes, net of issuance costs of $1,773		44,777
Equity component of transaction costs for 2020 Convertible Notes	$ 1,773	1,773
Net income (loss)		450	(9,700)
Balance at end of period		141,063	86,350
Common Stock
Balance at beginning of period		$ 34	$ 33
Balance at beginning of year, shares		33,678,840	33,265,629
Exercise of common stock options, shares		455,573	18,693
Issuance for employee stock purchase plan, shares		39,411	32,826
Vesting of restricted stock units, shares		195,280	101,483
Shares withheld for employee taxes upon vesting of RSUs, shares		(63,064)	(33,503)
Balance at end of period		$ 34	$ 33
Balance at end of year, shares		34,306,040	33,385,128
Additional Paid-In Capital
Balance at beginning of period		$ 447,297	$ 428,729
Exercise of common stock options		4,454	246
Issuance for employee stock purchase plan		357	444
Shares withheld for employee taxes upon vesting of RSUs		(1,358)	(488)
Stock-based compensation		4,951	4,263
Equity component of 2020 Convertible Notes, net of issuance costs of $1,773		44,777
Balance at end of period		500,478	433,194
Accumulated Deficit
Balance at beginning of period		(359,899)	(337,177)
Net income (loss)		450	(9,700)
Balance at end of period		$ (359,449)	$ (346,877)

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2020	Nov. 30, 2018
Equity
Fair value of warrant	$ 8,043
Third Amendment to the Commercialization Agreement
Equity
Number of shares that can be purchased		1,041,667
Exercise price of warrant (in dollars per share)		$ 19.20

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock-Based Compensation Included in Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation
Total stock-based compensation expense	$ 4,951	$ 4,263
Research and development expenses
Stock-based compensation
Total stock-based compensation expense	770	567
Selling, general and administrative expenses
Stock-based compensation
Total stock-based compensation expense	$ 4,181	$ 3,696

Stock-based Compensation - Narr

Stock-based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	May 31, 2015
Stock-based compensation
Unrecognized compensation cost related to outstanding options	$ 48,713
Period over which unrecognized compensation cost is expected to be recognized as expense	3 years
Employee Stock Purchase Plan, Purchase Price Percentage	85.00%
Issuance for employee stock purchase plan, shares	39,411	32,826
Proceeds from issuances of common stock from employee stock purchase plans	$ 357	$ 444
Total purchased proceeds	79	100
Share-based Compensation	$ 4,951	4,263
Performance share units
Stock-based compensation
Vesting period	3 years
Weighted-average grant date fair value of shares granted	$ 28.81
Share-based Compensation	$ 397	$ 15
Performance share units \| Minimum
Stock-based compensation
Vesting Percentage	0.00%
Performance share units \| Maximum
Stock-based compensation
Vesting Percentage	200.00%
Restricted Stock Awards And Restricted Stock Units
Stock-based compensation
Vesting period	4 years
2014 Stock Incentive Plan
Stock-based compensation
Shares of common stock authorized for issuance (in shares)			2,700,000
Increase in number of authorized shares on the first day of each fiscal year, as a percentage of outstanding common stock (as a percent)	4.00%
Shares of common stock remaining available for future grant	946,952
2014 Stock Incentive Plan \| Stock options
Stock-based compensation
Vesting period	4 years
Contractual life	10 years
2014 Stock Incentive Plan \| Stock options \| Minimum
Stock-based compensation
Period following termination date vested options are exercisable	1 month
2014 Stock Incentive Plan \| Stock options \| Maximum
Stock-based compensation
Period following termination date vested options are exercisable	3 months

Stock-based Compensation - Su_2

Stock-based Compensation - Summary of Restricted Stock and Performance Share Activity (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Performance share units
Number of shares
Balance \| shares	99,400
Granted \| shares	187,978
Performance adjustment \| shares	(4,155)
Balance \| shares	283,223
Weighted-average purchase price per share
Balance \| $ / shares	$ 15.90
Granted \| $ / shares	28.49
Performance adjustment \| $ / shares	15.90
Balance \| $ / shares	$ 24.26
Restricted stock units
Number of shares
Balance \| shares	849,679
Granted \| shares	725,422
Vested \| shares	(195,280)
Forfeited \| shares	(7,263)
Balance \| shares	1,372,558
Weighted-average purchase price per share
Balance \| $ / shares	$ 17.10
Granted \| $ / shares	21.34
Vested \| $ / shares	17.83
Forfeited \| $ / shares	17.63
Balance \| $ / shares	$ 19.23

Stock-based Compensation - Su_3

Stock-based Compensation - Summary of Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Stock option activity
Outstanding	3,955,887
Granted	574,783
Exercised	(455,573)
Cancelled	(40,883)
Outstanding	4,034,214	3,955,887
Exercisable at end of period	1,916,510
Weighted average exercise price per share
Outstanding	$ 16
Granted	21.39
Exercised	9.78
Cancelled	19.36
Outstanding	17.44	$ 16
Exercisable at end of period	$ 16.55
Stock option activity, additional information
Outstanding Weighted-Average Remaining Contractual Term	7 years 9 months 18 days	7 years 6 months
Outstanding Aggregate Intrinsic Value	$ 5,904	$ 21,257
Exercisable at end of period, Weighted-Average Remaining Contractual Term	6 years 8 months 12 days
Exercisable at end of period, Aggregate Intrinsic Value	$ 3,550

Stock-based Compensation - Su_4

Stock-based Compensation - Summary of Valuation Assumptions Used (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants
Risk-free interest rate	1.50%	2.60%
Volatility	65.50%	63.30%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days

Commitments and Contingencies (

Commitments and Contingencies (Details)

Nov. 06, 2019lawsuit

Oct. 18, 2019lawsuit

Sep. 11, 2019item

May 09, 2019patent

Sep. 26, 2018lawsuit

Jul. 12, 2018lawsuit

May 04, 2018lawsuit

Feb. 22, 2018patent

Mar. 24, 2015patent

Oct. 31, 2019lawsuit

Mar. 31, 2019lawsuititem

Nov. 30, 2018patent

Mar. 31, 2020patentlawsuit

Commitments and Contingencies

Period that gives the Company a 30-month stay of FDA approval while the parties have an opportunity to litigate

45 days

Stay period before FDA can issue a final approval unless it is terminated

30 months

Number of lawsuits filed

Purdue Pharma, L. P. patent infringement suits

Commitments and Contingencies

PTAB duration for issuing decision

1 year

Purdue Pharma, L. P. patent infringement suits | Maximum

Commitments and Contingencies

PTAB extended duration for issuing decision

6 months

Purdue Pharma, L. P. patent infringement suit, District of Delaware

Commitments and Contingencies

Number of patents allegedly infringed | patent

Purdue Pharma, L. P. patent infringement suit, District of Massachusetts

Commitments and Contingencies

Number of patents found not infringed | patent

Teva Litigation

Commitments and Contingencies

Stay period before FDA can issue a final approval unless it is terminated

30 months

Number of patents allegedly infringed | patent

Number of patents found not infringed | patent

Number of patents listed in FDA Orange Book | patent

Number of terms or sets of terms addressed | item

Number of terms or sets of terms in dispute | item

Opioid Litigation

Commitments and Contingencies

Number of counties filed lawsuits

Number of lawsuits filed

Number of lawsuits currently stayed

Number of lawsuits dismissed

Payor Groups and Warminster Township

Commitments and Contingencies

Number of lawsuits filed

Number of lawsuits currently stayed

Number of payor groups | item